vaccine-preventable subject free possible current such assert subsequent additional digital re-hosted educational non-commercial computer-extracted Computer-extracted such unusual odd Original 2021-11-05 Vaccine-Preventable * wº- –- responsible additional Vaccine-Preventable commercial responsible current upper critical first Greek other 5th medical Vaccine-Preventable Other Other latin laboratory Other live bacterial wiral human =- live t- lable Clinical viral first human Other Clinical oral global lable Last indigenous irst recombinant Two-dose civilian lable C-1 Reportable Waccine-Preventable 1950-2003 1962-2004 ................ 272:1133-7 |-2 |-3 |-4 |-5 |-6 local current acellular single-dose single acellular single-dose vial acellular single-dose acellular single-dose single-dose vial single-dose generic 15-dose vial acellular single-dose acellular sanofi single-dose 10-dose vial generic 15-dose vial single-dose influenzae single-dose – single-dose single-dose vial single-dose vial single-dose single-dose immune single-dose single-dose single-dose single-dose single-dose vial single-dose influenza single-dose live single-dose 10-dose vial 10-dose vial sanoſ single-dose single-dose single-dose vial single-dose vial single-dose vial single-dose single-dose —- single-dose single-dose 7-valent single-dose – 23-valent single-dose vial 5-dose vial sanoſ single-dose 10-dose single-dose | multi-dose | Japanese _|_JE-VAX sanoſ single-dose vial single-dose single-dose single-dose 20-dose live oral | 4-capsule YF-Vax 5-dose vial 521-7468 detailed basic useful Many available additional —- human indigenous “ —- foreign “ infectious –- infectious most foreign –- specific single specific single —- related basic active passive —- _-r own —- permanent own _- human human effective few complex primary foreign “ nticien such capable specific cell-mediated foreign effective live alive such Other such long certain effective good other important human other temporary common last full-term same certain red small intravenous large whole red major homologous homologous human heterologous human many different many different high high other lesser several available human polyclonal many different single antibody-producing single specific single single related certain infectious many certain colorectal ovarian chronic lymphocytic non-Hodgkin infectious available syncytial other other other specific other – monoclonal antigen-specific cellular passive temporary active many similar natural active natural general infectious many certain many active similar natural similar natural viral bacterial protein-based polysaccharide-based wild effective similar natural effective more similar better Many maternal such nutritional basic live different live available live available whole Fractional protein-based polysaccharide-based bacterial Most polysaccharide-based wild serial wild * º-º- ºr- small immune live ineffective such wild much milder natural adverse identical natural wild effective severe certain human original disease-causing live oral possible transplacental poor n sensitive fragile available live viral yellow available yellow new live bacterial i oral oral available immune fractional polysac- live 3-5 humoral alive entire live present antibody-containing general protective protective second third natural humoral cellular periodic supplemental available available whole viral whole whole available available human available available united certain available pneumococcal meningococcal available pneumococcal meningococcal pneumococcal meningococcal independent able immunogenic T-cell—independent less functional younger inactivated “ functional polysaccharide little late independent pneumococcal meningococcal genetic available thorough common more American current familiar important appropriate Specific antibody-containing live simultaneous nonsimultaneous different subsequent same immune same immune antibody-containing live nonsimultaneous different subsequent same certain such immune parenteral live enough viral live necessary least necessary necessary antibody-containing live low anti-Rho rubella-susceptible other last possible necessary few immune significant live other available syncytial young intravenous human other human live monoclonal syncytial simultaneous decreased adverse eligible important appropriate early unvaccinated vaccine-eligible same same sanofi-pasteur same different live i other live parenteral less second effective yellow single-antigen yellow live parenteral live second yellow oral oral oral other other available likely same yellow live live oral oral oral live other inactivated live other multidose multidose youngest Most more adequate same optimal Table minimal minimal necessary up-to-date international minimum minimum minimal earlier minimal first younger older second consid- few minimum unlikely negative recommended reliable preferable reliable preferable minimum valid 4-day minimum valid greater minimum certain local specific 4-day next available recommended minimum minimum valid earlier significant final necessary necessary oral typhoid oral four-dose more long-lasting single multiple periodic additional single second immune second “ live long-lasting necessary recommended protective second third few notable periodic additional rare older active specific adverse extraneous primary adverse adverse true extraneous true adverse general least severe frequent least frequent common adverse local such accine adverse common – common such mild self-limited rare local severe due high local systemic few mild self-limited many common unrelated concomitant viral unrelated adverse frequent whole-cell com- systemic adverse common acellular adverse live such similar mild natural due serious adverse adverse live mucous nose upper influenza-like third severe anaphylactic other such antibiotic bacterial allergic life- allergic good prior public private significant adverse significant adverse adverse Most temporary serious adverse serious general similar serious adverse such general present adverse high acellular pediatric high adverse few true severe allergic severe anaphylactic •encephalopathy due due identifiable identifiable ºwithin further pediatric pertussis-containing greater shock-like hypotonic inconsolable more temporary temporary severe recent antibody-containing true anaphylactic severe anaphylactic allergic medical severe urticaria appropriate allergic common animal yellow able anaphylactic anaphylactic-like adverse reasonable yellow influenza severe severe Egg-allergic prior anaphylactic neomycin allergy delayed-type cell-mediated delayed-type liquid commercial responsible allergic natural dry natural natural natural same lesser medical other natural vial intravascular synthetic medical vial synthetic natural natural allergic common contact-type latex-containing injection-procedure—associated diabetic anaphylactic natural other anaphylactic dry natural natural pregnant theoretical fetal theoretical pregnant pregnant Susceptible pregnant severe due uncontrolled oral live isolated safe • > alternate-day short topical significant immunosup- congenital immunosuppressed same live least large more prednisone more weight such alternate-day short less high-dose topical live human immune therapeutic monoclonal other opportunistic live live poor functional immunosuppressed human immuno- general same other Live-virus severe asymptomatic severe due hematopoietic neoplastic own autologous other transplant vaccine-preventable autologous certain vaccine- preventable inactivated influenza immunocompetent meningococcal pneumococcal other available peripheral umbilical annual immunocompetent meningococcal insufficient |General adverse severe live inactivated common such upper invalid certain true Such * invalid common invalid minor Non-vaccine-related unrelated anaphylactic certain such low-grade upper Several large young small multiple subsequent large small adverse such mild Low-grade necessary immune antibiotic antiviral live-virus tic adverse critical healthy healthy live pregnant immunosuppressed noncommu- nicable human common older eligible low passive vaccine-preventable maternal certain low chronological initial gestational likely older larger unknown initial count- ed additional first premature chronological chronological stable consistent Non-Vaccine-Related available such true relevant adverse sudden hereditary first-degree immune potential same most m false-negative same more most routine available such available serious adverse difficult few necessary severe time-efficient generic Most familiar minor medical last open-ended previous additional such high immune immunodefi- oral last immune healthy last last immune live last few unreported pregnant pregnant pregnant pregnant Red American recom- American opportunistic hematopoietic Infectious American important public safe efficacious important appropriate essential high own Vaccine-preventable lowest wild-type continued vaccine-preventable low several possible new suboptimal sustainable crucial vaccine-preventable unprotected other such severe social economic physical many ultimate late better optimal suboptimal other lower older pneumococcal racial Low-income greater underim- inner varicella vac- second low important fewer consistent influenza older least Sustainable High one-time short-term necessary effective such other specific such low successful current most sufficient least unvaccinated up-to-date necessary high other low knowledgeable capable new public private diagnostic high public private governmental nongovernmental medical other specific effective high sustainable specific measurable Second governmental personal medical potential necessary appropriate personal Much personal critical medical essential several most healthcare accurate own actual flexible defined necessary representative appropriate next second same summary specific substantial effective personal critical sufficient high desirable variable effective single different different small longer-term new other other possible diverse final more own other individual successful other knowledgeable appropriate statistical educational educational other such informal local professional actual such electronic different face-to-face e-mail cost-saving last several public private Many federal other available periodic possible single overall single more private large private electronic previous previous basic individual various potential such specific such available available effective gradual consistent private substantial median up-to-date public private state- public private annual widespread powerful Other substantial certain other immu- favorable vital medical electronic critical applicable legal such available available easy easy active medical —reflect current up-to-date new necessary complete accurate School-based public community-based primary quick such important new alternative available = population-based computerized geographic complete medical single reliable enrolled accurate additional immuniza- individual geographic younger operational population-based age-group federal local key federal available powerful recom- pediatric likely reluctant likely positive true many necessary useful next additional Reliable —powerful likely -verbal verbal higher due due due due effective effective various available computer-generated weekly other preventive other aggressive overdue local technical public private due due due due different overall ºt- computer-generated due T- such “ eligible several many simultaneous injectable immune adverse scientific available missed larger well-child Other large institutional bureaucratic such many different nonphysician direct such other positive eligible simultaneous additional responsible knowledgeable responsible higher general available professional greater effective other knowledgeable valid additional appropriate immu- unknown physical psychological such long specific such clinic many possible knowledgeable such eligible important a- such knowl- reliable direct supportive encouraging critical provider-based American high public public clinic cover- underimmunized cost-effective underimmunized private reg- prime general such potential specific significant public pharmaceutical safe effective adverse minor self-limited rare serious key active vaccine-preventable same adverse true adverse current vaccine-preventable likely adverse reportable vaccine-preventable public public critical decreased vaccine critical healthy lower rare sound several other similar willing vaccine adverse true unrelated public higher other medical pharmaceutical healthy healthy healthy lower sick possible rare adverse public many local widespread potential large universal human-directed strict regulatory dynamic necessary adjust oral global actual global continuous other pharmaceutical undergo human clinical clinical serious few last last several few several already-licensed adverse serious safe effective clinical rigorous potential outweigh common such injection-site small rare many largest inadequate possible rare essential vaccine-associated adverse public own public rare unusual healthcare new rare patient criti- cal particular high certain possible current postlicensure public ble rare large-linked rare specific vol- long-term unanswered clinical clinical individual certain adverse specific national significant adverse passive general local total large small additional significant medical certain local unknown adverse Serious adverse life-threatening serious additional medical full possible serious follow-up able primary new rare adverse patient particular adverse intussuscep- anaphylactic personal available 800-553-6847 common rare local systemic intrinsic recent adverse intrinsic individual vaccine-associated paralytic technical due natural More adverse plausible adverse specific clinical strong anaphylaxis natural positive clinical greater specific unvaccinated adverse other Large-Linked potential Such stud- informative costly time-consuming assess- single severe passive clear vaccine adverse high- active large-linked large computerized medical such single-provider such comple- adverse passive economical rapid medical more approxi- various available recent scientific indi- vidual certain adverse such similar regional infor- clinical vaccine individual Large-linked individual adverse better * prominent whole-cell scientific i several vacci d public epidemic public certain adverse medical serious adverse certain available effective rare available federal key contraindica- i available other possible Other —vaccine expira- prescribed prior administra- same corrective available available important optimal same more spe- minimum • same important effective greater serious adverse local dose unrelated medical such such pediatric serious adverse general present adverse Most temporary individual allergic American serious adverse most minor upper low-grade local moderate prior antimicrobial infectious utted unºſº unrelated clinical vaccine anaphylactic available familiar cardiopulmonary certain adverse reportable available secure 877-721-0366 20849-1 one-page 877-721-0366 valuable ongoing safest rare private available multiple legal understandable medical public private available responsible other available certain few certain religious personal basic devel- effective specific extensive up-to-date factual appropriate empathetic essential misinfor- available helpful effective public common unimmunized unimmunized certain potential vaccine-preventable unimmunized critical American permanent adverse current future new toxin-mediated i i diphtheritic late aerobic gram-positive specific gram-positive genetic severe selective normal other nor- severe toxigenic responsible local responsible major low severe toxigenic inadequate • 2-5 1-10 mucous mucous clinical tonsillar —genital anterior indistinguishable common blood-tinged white apparent poor systemic antibiotic common substantial systemic exudative 2-3 insidious Early low-grade bluish-white small high soft patient greyish-green black minimal forcible Extensive severe rapid high severe submandibular anterior lymphadenopathy characteristic cutaneous common responsible high natural other m recent nontoxigenic less other toxigenic Other mucous vulvovaginal attributable local abnormal cardiac early fatal soft frequent third fifth diaphragmatic Other due higher younger older little last clinical imperative presumptive critical tonsillar selective local attributable common hemolytic i clinical Other direct clinical diagnostic antibiotic positive presumptive low nonprotective commercial several available available 404-639-8257 other adequate provisional clinical appropriate maximum less contagious consecutive negative younger old old older 7- 10-day oral cutaneous non- clinical highest highest significant Native geographic asymptomatic high asymptomatic several variable pres- less more Effective antibiotic major 1940-2004 rapid widespread high cutaneous nontoxigenic cutaneous most lower 1980-2004 older older Most unimmunized immunized current inadequate 1980-2004 many protective rare endemic Native 5-14 15-24 25-39 40-64 toxigenic classic other major former More entire epidemic due several routine early early toxigenic available available pediatric available similar younger pediatric older pediatric available— 5-12.5 pediatric older 11-64 primary protective greater clinical acellular usual 15-18 third fourth third valid pediatric younger old first primary older first third second primary primary fourth fourth fifth recom- fourth fourth last optimal last first least last dose next frequent local adverse older primary prior rimary diphtheria-containing more unvaccinated older first least third dose second first single unvaccinated older recommended subsequent active common self-limited palpable several other systemic common local diphtheria- tetanus-containing extensive painful severe high severe local severe systemic such severe allergic prior additional local systemic common systemic allergic severe minor additional cutaneous toxigenic appropriate preliminary clinical presumptive strict least negative close other oral close nasal antibiotic fewer unknown immediate pri- mary current more diphtheria toxoid-containing recent Other younger adequate antibiotic additional 10-day other preventive acellular young available due preventable former pandemic fatal character- convulsive skeletal 5th clinical fatal human same specific protective passive gram-positive anaerobic sensitive resistant usual other Manure-treated large agricultural significant human tetani clinical minimum human 70-kg * * gram-positive spore- human ng/kg central nervous 3-21 clinical local common rare common spasms 3-4 complete newborn protective passive low several central nervous peripheral spinal sympathetic nervous typical clinical unopposed autonomic nervous central nervous longer higher neonatal clinical different same anatomic many fatal rare ear present middle cranial facial common first trismus abdominal Other episodic rapid last several newborn protective unhealed umbilical unsterile common more rare vocal sustained nervous abnormal common Secondary hospital-acquired elderly common autopsied recent likely fatal older unvaccinated obvious direct clinical demon- foreign tetanic supportive adequate critical single available other last dose last dose contagious practical useful proper important active passive primary tetanus clean minor uncertain early temporary protective encoun- populated hot organic intestinal major minor recent higher likely elective deep contagious vaccine-preventable infectious contagious 1947-2004 early late late notifiable ~0.05 recent all-time 1980-2004 older younger younger last younger 1980-2003 younger older younger young injection-drug late primary high recent available acute available other * frequent common Other insect other outdoor 1991-1995 1991-1995 < 40- 5-12.5 pediatric older 11-64 intravenous other chronic least primary injection-drug last fewer unknown prior formaldehyde-treated equal higher available single-antigen pediatric available Pediatric similar younger pediatric older pediatric available primary older younger greater minimal protective protective complete clinical last last rare last minimal protective small minimal protective other clean last fewer acellular usual second third fourth third valid pediatric younger old first older first third second primary fourth fourth fourth fourth first last Primary 6-12 local systemic common systemic most optimal last least last dose next frequent local adverse older primary prior unvaccinated older primary first least third dose second single unvaccinated older recommended subsequent small active Adverse adverse common self-limited palpable several other systemic common local diphtheria- tetanus- extensive painful severe high severe local such generalized few peripheral neuropathy recent available brachial rare additional severe allergic ful f prior severe routine minor toxoid-containing other clean pediatric American other preventive acellular young available //www.cdc.gov/nip/recs/provisional_recs/default.htm preventable neonatal lar 1998-W 1998.3-5 infectious 20th common major more widespread more major small aerobic gram-negative fastidious special multiple antigenic active filamentous responsible clinical subsequent clinical Recent permanent toxin-mediated pulmonary recent present alveolar clinical contagious gram-negative active filamentous epithelial 4-21 similar upper 7-10 insidious runny low-grade 1-2 occasional similar common severe second paroxysmal 1-6 paroxysmal numerous due tracheo- i characteristic high-pitched cyanotic young ill normal first same paroxysmal younger gradual paroxysmal subsequent many minimal asymptomatic present asymptomatic classic classic reported uncommon recent older other susceptible unimmunized underimmunized Older first multiple high highest common pertussis-related secondary bacterial younger such common Other serious severe subdural rectal encephalopathy pertussis-related younger younger such urinary characteristic physical useful young atypical preferred positive fastidious difficult direct successful posterior selective antibiotic effective trimethoprim-sulfamethoxazole first rapid sensitive available certain bacterial antimicrobial molecular _-__mi=L 6-11 y 5-0 10-19 20-y useful nasopharyngeal low variable useful clinical difficult available clinical serologic national white present classical lympho- greater More available medical supportive communi- antibiotic effective such trimethoprim-sulfamethoxazole younger four-dose minimal first minimum dose minimum dose second human important respiratory airborne silent little distinct seasonal communicable secondary susceptible infectious cough Secular common 6-year reported annual fewer ~1 largest clear highest average annual recent older annual older demographic detailed informa- many useful epidemiologic highest greatest severe recent available current clinical least inspiratory posttussive other apparent clinical laboratory-confirmed compatible clinical appropriate endemic sporadic outbreak least other Vaccine-Preventable available probable formalin-inactivated clinical subsequent observational primary whole-cell effective serious little last Local such other mild systemic common severe systemic such hypotonic such develop- more purified adverse 5-10 common full 59-90 inactivated Several acellular different different available fourth fifth pediatric available sanofi equal available 2-phenoxyethanol single-dose available pediatric similar pediatric same single-dose several effective acellular effective whole-cell local systemic serious such high hypotonic acellular various pediatric single similar new similar clinical similar available 4- 8-week fourth third other indicated fourth certain fourth fourth least least third unlikely additional fourth 15-18 15-18 15-18 17-20 same possible different necessary single single primary fourth necessary fourth primary fourth fifth whole same possible limited available available earlier acellular primary single different single single 5-year local systemic less adverse such younger young single single recent last tetanus toxoid-containing necessary younger single recent toxoid-containing least close immediate pregnant single same other permanent single least such diphtheria-containing first available available single single close single pregnant single separate other single acceptable primary fourth more primary age- valid primary final least last prior least prior protective least high separate fourth younger fourth fifth other pertussis- necessary same possible positive Other neurologic possible potential prolonged certain neurologic uncontrolled progressive other neurologic stable neurologic idiopathic cerebral other pertussis-containing necessary positive unknown neurologic neurologic additional —typical clinical culture-proven severe adverse common common whole-cell full smaller altered significant likely full smaller standard additional typical clinical such other other other certain local such frequent fourth systemic such low-grade common higher whole-cell self-limited severe such higher febrile persistent last- longer hypotonic hyporesponsive common fewer comprehensive adverse full Available substantial local fourth fourth fourth other systemic supplemental state- entire upper certain acellular substantial local self-limited entire fourth extensive fourth fifth fourth fourth improved whole-cell common adverse local such low-grade nonspecific such gastrointestinal same acellular serious adverse entire dose Low-grade same acellular identifiable severe higher other identifiable shock-like hypotonic inconsolable > allergic identifiable pertussis-containing previous toxoid-containing neurological severe local prior severe allergic due identifiable severe vaccina- such upper severe acute adverse subsequent higher due identifiable shock-like inconsolable longer communitywide precautionary adverse additional severe encephalopathy due identifiable pertussis-containing previous toxoid-containing progressive such uncontrolled severe local prior toxoid- least last Td-containing severe severe certain such higher persistent subsequent adverse stable such controlled cerebral American young antimicrobial i anti-vaccine untold acellular spinal spinal compatible recognizable first early next severe average older paralytic effective last wild-virus global eradica- next transient gastrointestinal stable small ether-insensitive minimal significant other ultraviolet primary multipli- gastrointestinal several local blood- central nervous anterior typical ultraviolet local central nervous variable clinical asymptomatic non-CNS paralytic able nonspecific clinical central nervous clinical abortive complete less poliovirus upper gastrointestinal abdominal indistinguishable other viral aseptic several similar last complete normal biphasic initial minor 1- major superficial deep asymmetrical most present permanent common paralytic most cranial spinal paralytic cere- brospinal diagnostic genomic wild high fourfold white wild inapparent asymptomatic immune fecal-oral important oral-oral seasonal tropical infectious susceptible greater susceptible infectious Oral-oral possible present stool 3-6 early maternal high continual paralytic immediate frequent primary natural susceptible paralytic early oral paralytic last paralytic endemic wild several i last imported recent direct vaccine-associated paralytic live oral 1980-2004 last unvaccinated several asymptomatic vaccine-derived unvaccinated least genetic early other first available monkey 2-phenoxyethanol • single-dose subcutaneous intramuscular effective • effective dose monkey single intestinal viral first fecal effective protective least immune paralytic local wild many complete effective single more other live-virus oral lifelong excellent intestinal lower low fourth fourth similar other exclusive paralytic sequential occur- vaccine-associated paralytic sequential humoral inactivated third fourth sequential complete complete complete paralytic available indigenous primary other first early second third = 1996-1999 sequential paralytic available whºs 6-18 4-6 fourth early available 4-6 complete necessary polio-endemic first second necessary immune third high preferred second third minimum minimum fourth fourth fourth fourth third fourth adminis- least fourth specific fourth necessary available routine complete minimum 5-component pediatric first same younger fourth fourth fifth older necessary immune small endemic epidemic eastern close wild specific current wild previous available unvaccinated prior standard third possible 1-2 6-12 available available least available single complete further supplementary supplemental complete necessary additional endemic full last necessary local serious adverse docu- local strepto- serious allergic paralytic rare adverse live oral available paralytic 5-10 exclusive paralytic identical Most healthy likely likely immuno- normal higher certain available paralytic older paralytic healthy average healthy average immunologic abnormal equal other overall normal overall first other able revertant similar last allergic further allergic anaphy- lactic such severe successful upper local prior current antimicrobial con- same individual clear allergic severe Last • free Last preliminary clinical paralytic appro- local appropriate viral single paralytic immediate vaccine-associated unvaccinated epidemic older uncertain widespread many paralytic more fewer last indigenous wild acute flaccid such national last wild-virus—associated indigenous additional intensive international free indigenous detailed national global substantial last international other bilateral multilateral Current global available paralytic new new syndrome permanent residual paralytic infectious more postpolio Post-Polio 14-534-0475 www.post-polio.org wild global global last indigenous wild virus-associated new paralytic late clinical secondary unencapsulated capsular cerebrospinal effective bacterial other invasive bacterial younger invasive younger younger influenzae gram-negative aerobic facultative dinu- • different a-f gram-negative invasive responsible distinct capsular invasive distant upper several normal common unencapsulated frequent human invasive unknown likely striking age-dependent common capsular protective invasive ug/mL unconju- long-term invasive anticapsular age-specific asymptomatic small common antigenic so-called anticapsular other genetic important genetic unknown single genetic many organ common invasive common clinical invasive pre- other other neurologic appropriate antimicrobial life-threatening focal severe common invasive common invasive due nontypeable unencapsulated invasive rare serious common small gram-negative invasive pleural middle appropriate positive neurologic effective antimicrobial important younger vaccine influenzae antimicrobial viable available rapid sensitive specific capsular negative false-positive similar aggluti- sensitive difficult invasive effective chloram- effective Ampicillin-resistant Ampicillin-resistant common life-threatening etiologic initial empiric out- i primary bimodal seasonal second contagious invasive certain particu- close institutional direct secondary reportable Serotype-specific incomplete national several active younger popu- invasive invasive younger invasive Three-hundred due unvaccinated age-dependent invasive older invasive invasive younger young 1990-2004 o 0-1 12-13 24-25 36-37 48-49 recent unvaccinated socioeconomic parental —school-aged -chronic three-dose primary Fifty-six eligible primary age-eligible fewer unknown younger invasive due unknown actual vaccinated large house- low socioeconomic low parental school-aged African socioeconomic younger maternal invasive secondary 600-fold higher general popu- younger older secondary first second third fourth secondary trans- Most low secondary effective younger older negative greater available similar other polysaccharide pneumococcal meningococcal typical T-independent age-dependent poor younger minimal polysac- ineffective effective T-independent T-dependent young class-specific useful first immunogenic available young different available 1985-1988 effective older variable immunogenic old functional young young utilize different available protective primary uncommon invasive such sickle-cell human invasive primary separate primary primary three-dose primary primary ACIP-Recommended 12-15 primary primary primary minimum least previous second third simulta- other immunologic subsequent younger interchangeable protective necessary primary older full current interchangeable primary dose influenzae entire current 15-59 least 2-6 ” dose dose 2-6 ” least previous least last least last unvaccinated single least last child single up-to-date three- four-dose catch-up invasive protective anti-PRP invasive susceptible possible general older older immune asymptomatic older invasive functional anatomic sickle hematopoietic unvaccinated older least pediatric available sanofi available app * protective invasive high-risk separate other single acceptable primary fourth more primary valid primary final least last prior least prior Hib-containing prior immune younger 0-1-6-month primary fourth prior same individual adverse adverse positive chronic same adequate off-label positive unknown same individual particular third older least second common such adverse local systemic similar concurrent individual serious adverse severe moderate severe upper younger immunologic same reportable healthcare invasive local American Red American invasive vaccine-preventable older influenzae invasive preventable acute viral infectious early Persian lifelong human live available immune common fatal single-stranded important responsible viral responsible antigenic important acidic short less systemic primary regional primary subsequent viral regional distal second initial other nasopharynx contagious viral universal fatal important light regional 2-3 5-7 clinical 10-12 higher * high mucous pathognomonic blue-white bright red buccal next downward discrete upper most involved same 5-6 Other more common younger older viral common 1985-1992 stiff residual many other higher young common rare degenerative central nervous due insidious progres- sive early higher spontaneous low-birthweight definable malfor- Atypical inac- pleural maculopapular petechial urticarial vesicular local severe immune young residual mild discrete short mucous clinical certain lym- typical several high younger severe bacterial high routine important molecular geographic viral urine public viral same likely more viral available enzyme-linked available diagnostic susceptible wild-type many negative negative positive previous single diagnostic positive other positive first false-negative negative first detectable least available indirect possible second speci- same same specific second indigenous other human asymptomatic large late 1950-20 1989-1991 late communicable greater secondary susceptible Secular epidemic actual More highest 2–3-year epidemic indigenous lowest annual school-aged younger younger first school-aged second dramatic school-aged largest younger first younger 5–19-year-olds highest lowest non-Hispanic higher non-Hispanic measles-associated death-to-case younger fatal largest annual important low low many large preschool-aged early experi- preschool-aged few second black likely white younger high other many young due wild smaller higher susceptible younger many other 1993-2004 low annual Most due preschool-aged 2-year-old fewer fewer low annual other other aggressive low elim- older high many prior second school-aged school-aged uncommon preschool-aged More several more largest pre- school-aged last large largest religious personal largest large measles-related pre- preschool-aged older low due recent high aggressive large maculopapular probable gener- higher noncontributory probable clinical probable possible local international local indigenous indigenous available //www.cdc.gov.nip/publications/surv-manual/default.htm live inactivated fre- Two-dose unique atypical wild-type mumps-rubella-varicella original high live fewer original available live available * individual freeze-dried sterile preservative-free small human noncom- municable approxi- similar first primary Most vaccine th second passive other Most first first serologic vaccine-induced lower natural serologic epi- demiologic vaccine-induced long-term Most vaccinated anamnestic available secondary successful minor least least other adoles- first first measles-containing least second first second first catch-up earlier first additional other acceptable minimum valid primary 12-15 medical first second possible less first valid Self-reported parental other acceptable permanent medical specific indicated other older medical least least measles- rubella- other acceptable pregnant medical acceptable special other post-high educational medical international other post-high educational potential high-risk large sus- ceptible technical other post-high other acceptable live other acceptable first prior other measles-containing first second least previous medical higher general least overall medical medical medical medical nonmedical full patient-care tible medical private public possible low live live second least first acceptable medical medical first live last unknown unknown unvaccinated prior medical cost-effective susceptible necessary other acceptable timely endemic epidemic many other certain unvaccinated least first last unknown unknown neces- sary temporary maximum susceptible younger highest live passive susceptible adverse common adverse susceptible higher Most asymptomatic Measles- rubella-containing low susceptible temporal clinical greater higher thrombocytopenic other rubella-containing other other susceptible rare rare Most minor anaphylactic rare uncommon possible second independent nongovernmental American available current severe prior anaphylactic serious measles- mumps- anaphylactic measles- other such serious allergic chick egg-allergic low skin-testing allergic i egg- allergic prior special other pregnant due large virus subsequent least immunocompromised susceptible immunocompromised general large more least high-dose low-dose short-course less alternate-day topical intra-articular high systemic component least severe severe unusual adverse severe immunosup- variable asymptomatic symptomatic other measles-containing theoretical other clinical such asymptomatic severe immuno- Age-specific severe HIV-infected other measles-containing severe HIV-related ul total severe acute ill potential such mild upper antibiotic other recent upper previous subsequent immune whole red intravenous immune such concen- intravenous thrombocytopenic significant direct vaccine-induced natural greater potential greater subsequent previous previous such other measles-containing same admin- measles-containing same measles-containing least theoretical least favored less less average less recon- stituted same first—give skin American Red American global fatal congenital health-care 54:1229-31 global autistic second acute viral * viral filterable frequent military military common aseptic common i military ſt same cross- single-stranded various ultraviolet cerebrospinal regional regional such inf 12-25 tiSSueS characteristic aseptic nonspecific low-grade • 14-18 common infected unilateral single salivary many asymptomatic additional nervous aseptic common clinical inflammatory cerebrospinal post- higher -l. absent many such rare mumps testicular common postpubertal many postpubertal bilateral abrupt last testicular rare ovarian infrequent reversible single many temporal few unilateral vestibular sudden compatible symptomatic rare Other less common clinical particular clinical clinical acceptable nasopharyngeal buccal buccal upper best viral buccal viral simplest available sensitive other available detectable first few possible symptom acute-phase human asympto- matic nonclassical airborne direct infected —positive —significant active similar infectious active reportable 1968-2004 relative highest older routine correlat- 1980-2004 º high single more many many laboratory due complete appropriate many true 5-14 early 5–9-year late older older -40 urban suburban serologic clinical unilateral bilateral self-limited other other apparent short-lasting live available single-antigen measles-mumps-rubella individual freeze-dried sterile preservative-free small human noncom- single measurable similar single vaccine-induced greater lifelong vaccine least mumps-containing first mumps-containing unilateral bilateral self-limited other salivary other first Mumps-containing least second first first second second available first second second dose long- first available second first adolescent catch-up medical least least measles- rubella- other acceptable high second valid Self-reported parental other acceptable permanent medical specific indicated other older immune physician-diagnosed live first acceptable “ equivocal susceptible Live 5- likely recognizable arbitrary necessary immune effective harmful adverse such joint attributable compo- adverse large-scale physician- rare rare allergic severe chick allergic few vaccine evi- inadequate aseptic sensorineural severe allergic prior anaphylactic serious measles- mumps- anaphylactic measles- other such serious such egg-allergic low skin-testing predictive allergic egg-allergic prior routine special theoretic immune immunosuppressive low-dose less alternate-day topical immunosuppressive additional human severe mild upper antibiotic other antibody-containing immune whole red intravenous immune serocon- least antibody-containing less refrig- average American relative vaccine- preventable little “ third separate medical common “ German viral viral acute widespread Australian congenital maternal early first such eastern western single other unstable lipid low respiratory regional mitotic subclinical first rare older lymphadenopathy upper maculopapular 14-17 little red variant distinct clinical German low regional 5-7 12-23 low-grade 14-17 second pruritic hot last several posterior cervical many integral Other soft diagnostic common same last rare chronic rare secondary low thrombocytopenic common cerebral intrarenal last Additional late 1964-1965 main surgical/spontaneous retarded emotional disastrous early fetal spontaneous many first fetal rare overall third greater uncomplicated common sole congenital espe- fourth includ- such ventricular possible mental other progressive older low high many subclinical reliable acute positive viral rubella-specific significant acute- fetal spleen clinical serologic urine cerebrospinal diagnostic viral intensive many routine valuable epidemio- viral common significant acute- possible False-positive positive infectious positive available available preferred Enzyme-linked sensitive available easy diagnostic sensitive fourfold greater diagnostic recent rubella-specific primary rapid sensitive available false-positive due i human true more • late airborne trans- insect subclinical asymptomatic highest contagious contagious more large susceptible Secular notifiable largest annual fewer moderate due low annual independent available careful longer 1966-2004 younger older 1980-2004 1980-2003 mid- Hispanic young largest annual due susceptible young Most reported foreign-born most Latin American most Clinical clinical generalized maculopapular higher lymphadenopathy recent generalized probable clinical virologic laboratory-confirmed laboratory clinical laboratory-confirmed congenital congenital peripheral pulmonary pigmentary developmental infection-only clinical compatible clinical probable probable other consistent probable eye-related single compatible higher joint human other live rubella-infected aborted human fibrob- communicable available nonpregnant individual i single-antigen freeze-dried sterile preservative-free small human safe immunogenic older serologic single More vaccinated clinical least Follow-up long-term lifelong similar single-antigen Several low detectable unknown uncommon clinical fetal vaccine-induced pregnant least least first first rubella-containing least second first second second available first second second long-term available second first first second first older least medical least least measles- rubella- other acceptable high second susceptible acceptable pregnant pregnant valid Self-reported parental other acceptable permanent medical specific indicated other older other live first equivocal serologic rubella-susceptible acceptable routine unvaccinated congenital acceptable pregnant positive appropriate pregnant immune laboratory important pregnant detectable unreliable many many reliable previous reliable negative Such serologic medical cost-effective susceptible timely prior necessary other acceptable immune effective harmful adverse such attributable common lymphadenopathy adverse common rare rare susceptable arthritis-like Population-based severe such joint susceptible susceptible susceptible postpubertal acute arthritis-like transient peripheral neuritic such acute other chronic seronegative seronegative unimmunized neuropathy severe allergic prior pregnant pregnant fetal next immune immunosuppressive low-dose less alternate-day topical immunosuppressive asymptomatic symptomatic severe mild upper con- current antibiotic other antibody-containing immune whole red intravenous immune serocon- least adminis- antibody-containing necessary Previous human immune contraindi- anti-Rho immune serologi- serious pregnant pregnant likely pregnant next pregnant other theoretical pregnant likely next theoretical 1971-1989 routine pregnant pregnant pregnant such subclinical susceptible susceptible vaccine-induced maximum theoretical low routine small theoretical pregnant refrig- average low several high •Intensive indigenous susceptible young premarital possible at-risk special supplemental susceptible immune important susceptible American American pregnant congenital rubella-containing congenital preventable infectious Primary infectious vesicular vesicular healthy other first latent regional other such sensory secondary viral varicella viral regional sensory 14-16 10-21 1-2 2-4 pruritic pruritic highest centripetal mucous superficial clear erythematous several present several macular same successive clinical healthy severe higher gastroin- severe progressive high extensive vesicular high prolonged primary healthy second common other viral natural wild clinical detectable young younger immunocompromised skin central nervous pulmonary hepatic extramedullary cranial Most fifth cranial few systemic available last other severe mild self-limited common secondary bacterial skin central nervous common outpatient medical serious viral bacterial Secondary bacterial common younger nervous aseptic common good infrequent cerebral common unusual unknown dramatic aseptic hemorrhagic clinical healthy rare Most normal healthy older < 1-14 15-19 20-29 high serious high organ fulminant pneumo- maternal overwhelming high severe fetal passive maternal prior due passive maternal first maternal newborn low muscular cortical small congenital primary maternal first low less low Rare congenital maternal virologic maternal ear- exact unknown useful necessary atypical adverse wild-type such laboratory frequent vesicular wild-type severe unusual specific antiviral rapid clinical available sensitive available available several real-time unavailable direct sensitive meticulous fresh fluid-filled Other such nasopharyngeal bronchial desirable skin positive such likely viral viral positive viral negative reliable valid distinctive subclinical unusual necessary useful available Available clinical available standard early 1-2 4-5 indirect fluorescent indirect immune latex enzyme-linked sensitive specific available available sensitive rapid sensitive commercial false-positive useful lower Commercial sensitive vaccine-induced potential false-negative routine significant standard commercial available false-positive common high reli- able 404-639-0066 404-639-3667 common tropical more distri- rural insect common tract secre- airborne direct acute distinct seasonal highest early highest lowest tropical seasonal first contagious entire new contagious contagious more Secondary susceptible high Secular endemic adult- notifiable younger highest age-specific earlier older active varicella-related 1990-1994 1-4 5-9 to-14 15-19 20- active 5-9 reduced 10-14 15-19 notifiable Ninety-five first least live attenuated viral vesicular healthy general sequential embryonic small residual live attenuated identical equal higher plaque-forming = detectable More least Japanese moderate severe effective effective severe healthy second least second first clinical antigenic clinical healthy single similar separate long-lasting fewer fewer many Most recent younger younger several impotent inaccurate live viral 2.5-fold unvaccinated consistent higher less more more 12-18 necessary reliable reliable chick- susceptible severe simultaneous first second first second such equivalent first eligible vaccina- safe effective healthy same separate separate same least separate separate other other reliable typical such clinical single least healthy detectable single older first second desirable higher highest likely older high severe high other reliable uncertain likely cost-effective necessary seropositive available commercial sensitive 4-8 susceptible • cost-effective necessary full available vaccinated clinical infectious other sick susceptible susceptible healthcare potential vaccine-associated high serious such * age-appropriate age-appropriate typical —non-U.S. —all 1966-1997 parental non-U.S.-born atypical epidemiologic typical previc such valid other mild atypical effective subsequent prodromal vaccine-associated adverse post- preferred second outbreak second least older Adverse common such clinical local second local self- limited varicella-like effective effective maculopapular vesicular common second present maculopapular i second Most maculopapular similar Most vaccinated wild wild-type such postherpetic similar other severe allergic dose severe due immune immunosuppressive humoral asymptomatic humoral i immunosuppressive low-dose alternate-day topical severe cellular asymptomatic symptomatic age-specific higher 3-month impaired cellular greater live pregnant pregnant adverse insert American prenatal post- second other maternal—fetal pregnant 800-986-8999 severe ill potential such such upper antibiotic other active common rash antibody-containing immune whole red intravenous unknown potential antibody- same antibody-containing additional such least antibody-containing seronegative secondary few secondary clinical secondary wild several asymptomatic high such fragile frozen average frost-free low acceptable unsealed uninsulated small dormitory-style combi- capable preservative other antiviral short separate 800-9WARIVAX 800-982-7482 short possible central off-site difficult off-site dry appropriate average colder 800-9WARIVAX 3-4°F -20°C average human high available • clinical -susceptible pregnant susceptible negative likely impor- greater general expensive temporary high significant continuous i same 2- 4-bed direct neoplastic immunosuppressive less gram adequate maternal immune such congenital postexpo- pregnant possible longer detailed available //www.cdc.gov/nip/publications/acip-list.htm 625-unit last early severe severe available intravenous best anti-varicella clinical available neonatal less less neonatal pregnant possible effective late comparable recommended antiviral healthy cutaneous pulmonary long-term viral-mediated significant first last last strict entire longer antiviral active beneficial new cutaneous systemic antiviral specific initial antiviral American routine antiviral healthy healthy severe cutaneous pulmonary long-term short intravenous possible uncomplicated oral pregnant second third American other provisional updated Available varicella- healthy first first epidemic military infectious long serologic definitive other non-B primary hygienic passive immune long-term widespread natural several nonhuman stable stable low moderate higher fecal-oral present biliary present several clinical infected third longer • natural low high 10-12 15-50 specific symptomatic asymptomatic symptomatic clinical indistinguishable other acute viral abrupt abdominal last symptomatic younger asymptomatic older symptomatic fulminant higher older older substantial medical ill direct indirect pediatric annual other viral clinical detectable anti-HAV early anti-HAV detectable Anti-HAV present total anti-HAV anti-HAV anti-HAV total anti-HAV positive anti-HAV such viral helpful investi- molecular supportive endemic natural animal chronic fecal-oral person-to-person present rare present sewage-contaminated treated appreciable seasonal likely highest minimal personal sexual recent international Injection-drug Forty-five international illegal occupational fulminant solvent/detergent-treated noteworthy critical foodborne nosocomial rare neonatal intensive fecal developmental high fewer sporadic common common work-related available important asymptomatic unrecognized other large last high reportable largest low annual symptomatic low highest early similar anti-HAV general 6–11-year-olds older Anti-HAV highest Anti-HAV higher western other western Many high- late similar Many such high-rate intermediate-rate last several substantial high few older well-defined 1966-2004 = 1990-2004 1990-2004 certain religious high-rate high first-dose young subsequent clinical other viral clinical serologic necessary clinical discrete positive anti-HAV whole-virus whole available • i 2-phenoxyathanol available pediatric older younger protective seropositive single seropositive clinical seropositive protective effective clinical clinical high clinical high long-term immune current available kinetic protective Other cellular long-term unknown postmar- international other little successful high routine older average annual higher least routine average annual more successful high routine subsequent 12-23 routine available single older 6-12 6-12 initial subsequent initial available pediatric pediatric dose older deltoid 6-18 6-12 initial subsequent initial 6-18 first dose 6-18 first different interchangeable same preferable available acceptable first first pediatric first necessary first immuno- adverse same other Similar equivalent pediatric equivalent three-dose long-term first third least first second least second third least necessary older equivalent same single-antigen least second single-antigen pediatric illegal occupational recommended local older high first second dose necessary long-term first available complete initial immune different anatomic younger younger high-risk Other other illegal occupational occupational A-infected other due occupational Susceptible Susceptible solid routine local past such higher negative likeli- low cost-effective extensive geographic high older certain certain high available total high low anti-HAV diagnostic local mild self-limited systemic serious severe allergic vac- preservative 2-phenoxyethanol common serious adverse severe severe theoretical low uuith human negative effective administra- clinical large single possible more close sexual certain common-source HAV-infected transmis- high least injected live least least measles- mumps- rubella-containing live American active passive green several similar infectious separate early specific serologic first human early first complete serologic natural effective small double-shelled Other small circular double-stranded numerous nonhuman resilient infectious environ- least common infected chronic hepatocellular second die chronic 5th human yellow antigenic least infected chronic hepatocellular 60-150 average specific least asymptomatic Several well-defined hepatitis-associated antigenic subviral 22-nm spherical variable infectious complete infectious present complete detectable conventional soluble high high anti-HBs acute anti-HBs potential undefined recent anti-HBe detectable low clinical indistinguishable other acute viral average Clinical asymptomatic asymptomatic prodromal initial insidious quadrant abdominal icteric variable gray hepatic common other acute complete anti-HBs acute complete fulminant serious due chronic chronic chronic many infected chronic asymptomatic capable responsible HBV-related chronic active more estimated higher clinical epidemiologic clinical definitive early early 1-6 sensitive infectious chronic serologic acute anti-HBc recent detectable best serologic negative positive single chronic due due natural 1-2 dose immune sensitive low susceptible false positive undetectable useful infective higher protective anti-HBs positive appropriate milli-international protective supportive effective chronic successful other infective other other insect parenteral highest serous lower other such other unlikely 1-2 positive infected positive infected global common global global important transmis- sexual heterosexual homosexual Fecal-oral asymptomatic percutaneous injection-drug important other percutaneous other sharp medical small needle such fresh cutaneous other infective other direct mucous such hand-to-mouth hand-to-eye infective infective mucous environmental various infective other positive infected perinatal positive many infected different global high HBs.Ag-positive moderate HBSAg-positive low less HBs.Ag-positive most greater early chronic greatest most asymptomatic little acute high low low infectious present present reportable many reportable distinct serologic different available early injection-drug greatest acute new additional acute approxi- perinatal chronic 1978-2004 Other common sexual heterosexual early widespread uncommon uncommon general prevalent certain lifestyle highest infected frequent chronic high-risk injection-drug user high 10-20 35-80 illicit parenteral 60-80 active 35-80 3-10 20-80 3-6 30-60 1-8 10-80 frequent 1-2 15-30 multiple 5-20 3-10 first-time 3-5 available apparent uted several high large major infected multiple injection-drug immuniza- effective public private high-risk rapid high-risk low initial low comprehensive pregnant perinatal routine high plasma-derived 22-nm human safe effective unsubstantiated other human first recombinant second similar high-risk plasma-derived pediatric pediatric common yeast-derived final infectious viral complete available pediatric different interchangeable two-dose pediatric younger Engerix-B preservative residual other single healthy more adequate age-specific three-dose protective anti-HBs higher less * immune effective clinical complete normal protective high necessary other 40-mcg special ug ug ug 1-10 11-15 11-19 other immunocompromised 2-dose 3-dose more immunogenic specific 4-dose anterolateral lower least inch least inch other anterolateral valid serologic adequate vaccine-induced more • significant clinical anamnestic anti-HBs significant anamnestic anti-HBs significant normal immune additional available annual younger pediatric 1-2 intramuscular usual positive unknown third highest last least m preferable 2-month other good appropriate difficult vacci- third least second first least third earlier necessary longer HBs.Ag-positive unknown less chronologic initial gestational likely full-term low negative first stable full available same pediatric equivalent individual other younger potential positive unknown least first positive chronologic negative positive unknown first 5-component least high fourth younger fourth fifth other pertussis- necessary same other pertussis-containing necessary possible f total positive positive unknown [ 11-19 age-appropriate routine local deter- young highest flexible possible Asian active pediatric usual third dose minimum first minimum second third first third less minimum alternative alternative 10-mcg anti-HBs similar 5-mcg alternative 2-dose older pediatric usual less third dose minimum first minimum second third first third less minimum necessary third first least Alternative Heterosexual multiple long-term correctional sexual other multiple Injection-drug high injection-drug tible possible long-term injection-drug homo- sexual other high-risk large effective susceptible percutaneous permucosal public blood-contaminated such highest other allied equivalent pediatric equivalent three-dose long-term first third least first second least second third least necessary older equivalent same Other special behavioral medical high-risk other infected present certain such such important susceptible susceptible younger high unaccompanied high positive susceptible anti-HBs positive positive close local sexual local common medical Other unaccompanied high certain high common high certain such high specific casual such special such medical severe potential routine immune high cost-effective high higher such -.g endemic injection-drug endemic-disease HBSAg-positive cost-effective low such routine subsequent such i such —sex HBSAg-positive necessary HBs.Ag-positive final third fourth present anti-HBs present comprehensive sharp catch-up necessary significant low such public direct Several older primary additional additional first second three-dose second usual 6-month 1,4-month healthcare second detectable anti-HBs anti-HBs negative low detectable positive three-dose negative susceptible second usual • 1-2 second anti-HBs.Ag valid probable parenteral HBs.Ag-positive difficult negative anti-HBs possible negative true initial detectable vaccinated detectable true second anti-HBs sixth second expensive single positive previous further serologic anti-HBs negative “ seronegative total same high anti-HBs anti-HBs passive accidental percutaneous mucous sexual HBSAg-positive younger old primary Most high-risk cold low low valid current unavailable high chronic effective pre- chronic effective same different available first second third first third other pediatric initial 3-dose next chronologic third second fourth unknown positive possible important second unknown maternal first different reliable additional available chronic HBSAg-positive off-label positive unknown younger same other older percutaneous needle unknown available n positive unknown anti- adequate necessary anti- adequate necessary inadequate 1-2 inadequate immune adequate anti-HBs inadequate anti-HBs second 3-dose susceptible single last sexual last sexual more late chronic anti-HBs chronic chronic unvaccinated first second second nonsexual infected common adverse such i systemic adverse rare febrile neurologic newborn slight large population-based severe allergic Such allergic rare prior severe severe such upper inadvertent pregnant severe chronic pregnant eligible such suboptimal American comprehensive health-care occupational multiple neonatal infectious viral epidemic first epidemic least influenza infectious viral least 1918-1919 20th Spanish inactivated protective live influenza single-stranded nuclear • Single-stranded other wild Most natural stable less antigenic immunologic human subclinical epidemic > due sequential due serial irregular major 'ale larger ent protective new pandemic due genetic new antigenic last major antigenic prior wide geographic pathogenic avian person-to- necessary major minor same similar epidemic predominant widespread last different late major pandemic single high greater individual large severe fatal large tertiary epidemic lower major high respiratory high early respiratory epithelial docu- immunologic related general classic clinical abrupt nonproductive tracheal epithelial runny substernal last more such respiratory subsequent respiratory 5-10 1-4 related nonproductive rapid several frequent most secondary bacterial bacterial viral influenza viral uncommon high severe due Other chronic other chronic pulmonary older excess cardiopulmonary other chronic recent • influenza-associated older influenza- older higher higher • young certain young medical more • influenza-related greater predominant high healthy high medical comparable older American annual influenza least pandemic critical public local public federal available characteristic clinical amniotic certain viral demon- additional local individual significant influenza convalescent human specific least fourfold diagnostic clinic antiviral mos 496-1038 1-2 5-14 15-44 yrs 56-110 23-25 45-64 yrs 392-635 13-23 yrs 399-518 125-228 several epidemiological clinical serologic airborne available chronic large infected large upper susceptible direct indirect such influenza most peak tropical documented high-risk 1976-2005 high-risk medical major more total primary due epidemic influenza standard previous 5-year epidemic due consecutive available available intramuscular available final available pediatric 0.25-mL available preservative free available multidose thimerosal-free pediatric single-dose thimerosal-free single-dose younger available multidose reduced- free single-dose available “ free single-dose older same temperature-sensitive cold-adapted final residual single-dose other nasopha- least transmitted attenuated cold-adapted temperature-sensitive practical • effective healthy vaccine-induced antigenic effective elderly • effective prior immunologic effective |- effective healthy younger similar effective effective clinical effective elderly effective effective healthy healthy double-blind placebo- healthy culture-confirmed influenza culture-confirmed Other concomitant antibiotic randomized double-blind placebo-controlled healthy several influenza outbreak greater early effective more routine 1982-1983 effective old antibiotic fewer severe fewer febrile upper fewer due fewer due fewer antibiotic available other available patient accessible undertaken younger first other most influenza high-risk 6-35 previous older least influenza Other such intradermal subcutaneous topical older older Other • 6-23 i long-term pregnant • long-term chronic older chronic chronic such inactivated —pulmonary such congestive metabolic —renal such —any human cognitive other neuromuscular pregnant serious medical immunologic recent influenza-related more second third nonpregnant pregnant comparable nonpregnant high-risk medical pregnant pregnant Available Many protective low protective influenza demon- transient other such pneumococcal other similar clinical serious protective many higher nonpregnant comparable nonpregnant pregnant many many HIV-infected high-risk receive long-term high-risk younger • long-term likely elderly annual other outpatient high-risk high-risk healthy high-risk younger • essential protective severe essential institutional routine foreign previous high-risk current available influenza receive eligible healthy 6-23 healthy other influenza-related other younger annual high eligible available late own medical previous 6-10 previous healthy close high-risk high wild-type high-risk high eligible healthy other other specific simultaneous such Other live same same least possible Simultaneous Other Other live same same common adverse common rare lºcal previous last Recent systemic common immediate such allergic likely residual current small immediate appropriate occupational other allergic similar medical influenza potential admin- intradermal indicate local subsequent other small difficult rare such annual less true adverse lower severe pre- older medical general low greater greater prudent previous most high severe influenza adverse clinical attributable influenza clinical More approved healthy significant upper such other systemic unpublished significant other systemic reactive 12-59 serious adverse younger allergic severe chronic medical long-term inactivated anaphylactic other reactive other chronic pulmonary healthy higher serious adverse small such rare adverse available such immunosuppressed cardiac additional available high severe allergic severe younger older chronic medical other chronic cardiovascular such renal such long-term other wild-type other live-virus immunosuppressive residual other moderate severe clinical nasopharyngeal deferral adminis- antiviral influenza antiviral antiviral influenza antiviral coolant few visible present frost-free separate dormitory-style refrigerator-freezer frost-free separate 35°-46°F 2°-8°C systematic automatic total first upright dose- second other higher high-risk epidemic-related influenza-related older previous lower black Hispanic non- white fewer high-risk effective high-risk other residential long-term acute high-risk hospital outpatient high-risk high-risk necessary unvaccinated other prior appropriate influenza per- high-risk antiviral effective older new active dry uncomplicated older symptomatic oral uncomplicated older symptomatic more influenza older influenza-related antiviral current —effective influenza new influenza-related economic rapid preventive general high susceptible inactivated high-risk medical antiviral high-risk protective Other elective uncomplicated new necessary influenza-related economic out- rapid preventive unvaccinated high-risk weekly sporadic regional less widespread available special available //www.cdc.gov/ncidod/EID/index.htm American cold-adapted intranasal influenza Influenza-associated Available //www.cdc.gov/nip/publications/acip-list.htm health-care Hospital-based pneumococcal asthmatic interpandemic younger prospective healthy placebo-controlled double respiratory syncytial º- i other pneumococcal other More pneumococcal bacterial effective pneumococcal many antibiotic late pneumococcal first pneumococcal first conjugate pneumococcal lancet-shaped gram- positive facultative anaerobic * Gram-positive short complex important experimental * Type-specific primary antigenic type-specific Type-specific protective pneumococcal other additional serious few pneumococcal common invasive geographic common community- hospital-acquired higher higher elderly young elderly cerebrospinal younger older common healthy asymptomatic upper military many natural major clinical pneumococcal pulmonary common clinical pneumococcal invasive pneumococcal short single uncommon Other common pleuritic rapid poor rapid many pneumococcal community-acquired hospital-acquired common bacterial much higher elderly pneumococcal pleural pneumococcal overall high elderly fulminant clinical pneumococcal pneumococcal clinical neurologic similar other common bacterial nuchal cranial pneumococcal high elderly common common invasive clinical pneumococcal younger ive common clinical invasive invasive bacterial l- invasive bacterial younger routine pneumococcal younger i highest pneumococcal common middle least Middle ear frequent pneumococcal routine pneumococcal pneumococcal younger significant invasive º invasive pneumococcal invasive pneumococcal younger functional anatomic human high invasive higher African same certain racial ethnic particular certain American Indian invasive pneumococcal 2–3-fold definitive other sterile available capsular lancet-shaped suggestive difficult i normal pneumococcal white fewer epithelial gram-positive capsular capsular rapid clinical spinal pneumococcal positive large Several rapid pneumococcal other available sufficient invasive pneumococcal other common invasive pneumococcal resistant antibiotic available human asymptomatic early human direct person-to-person upper pneumococcal responsible such upper such pneumococcal high common early prevalent pneumococcal unknown pneumococcal More invasive pneumococcal nonbacteremic noninvasive overall invasive other sterile highest invasive pneumococcal young younger < 5-17 18-34 50-64 invasive invasive pneumococcal lowest older Invasive 1998-2003 pneumococcal young invasive pneumococcal younger prior invasive older young other close preliminary pneumococcal sporadic pulmonary pneumococcal common such correctional invasive high common invasive high 14-valent purified pneumococcal pneumococcal capsular different pneumo- 23-valent 7-valent coccal 23-valent 14-valent pneumococcal bacteremic pneumococcal cross- several capsular additional available available single-dose 5-dose pneumococcal capsular nontoxic younger pneumococcal available single-dose More healthy younger poor least healthy more certain underlying various clinical effective invasive effective pneumococcal significant underlying effective normal such high capsular bacteremic pneumococcal additional pneumococcal effective invasive effective pneumococcal young high-risk medical effective invasive effective severe pneumococcal pneumococcal significant vaccine-type non-vaccine-type more healthy large clinical invasive more fewer unvaccinated nasopharyngeal pneumococcal older older normal chronic cardiovascular pulmonary cerebrospinal pneumococcal splenic surgical chronic renal nephrotic such organ high-dose older asymptomatic symptomatic special social pneumococcal such certain feasible possible 2-week other immunosup- pressive possible complete uncertain unknown pneumococcal same different most single younger high-risk medical primary fourth same other routine separate younger minimum older least older full current least least 24- high-risk medical fewer 24-59 high high healthy single least older available high invasive pneumococcal other chronic least first high invasive pneumococcal additional last healthy certain highest higher serious pneumococcal dose available pneumococcal substantial improved multiple pneumococcal routine 23-valent older highest serious pneumo- coccal likely rapid pneumococcal high-risk previous highest severe pneumococcal less highest older functional anatomic multiple chronic renal nephrotic —functional other —transplant —chronic renal —nephrotic immunosuppressive long-term older second younger first primary common adverse pneumococcal local such common fewer severe systemic adverse rare clinical immunologic local severe common fourth first clinical higher primary most febrile attributable acellular same higher severe attributable pneumococcal severe Such allergic severe severe such upper pregnant adverse high pneumococcal pneumococcal possible coolant pneumococcal few least pneumococcal older population-based random-digit-dialed older older pneumococcal lower chronic high-risk other long-term More severe pneumococcal few pneumococcal high pneumococcal subsequent high significant pneumococcal American pneumococcal pneumococcal young pneumococcal vac- lower severe pneumococcal 3-5 few influenza pneumococcal pneumococcal pneumococcal invasive pneumococcal invasive pneumococcal protein- pneumococcal pneumococcal severe meningococcal first definitive spinal bacterial focal such sub-Saharan meningococcal first major meningococcal aerobic gram-negative several such cytoplasmic several other necessary complement-mediated main serologic distinct asymptomatic groupable invasive relative other such * sub-Saharan bacterial focal gram-negative invasive geographic other distant * 1992-1996 common hematogenous —petechial purpuric major certain outer pulsed-field elec- useful epidemiologic small colonized blood- many bacteremic cerebrospinal Clinical meningococcal common invasive meningococcal hematogenous similar other sudden other such mental invasive meningococcal abrupt petechial purpuric acute adrenal common meningococcal invasive meningococcal appropriate antibiotic many such neurologic meningococcal common functional anatomic meningococcal genetic such meningococcal upper active passive low higher low likely such higher invasive meningococcal least fatal patient higher meningococcal other similar sterile bacterial low antibiotic cerebrospinal gram-negative meningococcal cerebrospinal rapid specific false-negative common unreliable meningococcal -terminal -concurrent upper socioeconomic -active passive old •18-23 old * 2001:286:688-93 empiric antibiotic clinical meningococcal similar other bacterial empiric broad-spectrum third- appropriate Many effective Few penicillin-resistant endemic natural many asymptomatic most pathogenic groupable direct highest early meningococcal secondary Most secondary secondary general due meningococcal younger highest early early invasive low other young recent different last meningococcal due available due due meningococcal less sporadic Most additional meningococcal meningococcal endemic meningococcal several higher industrialized Meningococcal 1972-2004 1-4 5-14 15-24 25-39 40-64 Meningococcal 1991-2002 1996-2001 due recent first meningococcal current subcutaneous bacterial lactose * 10-dose preservative subcutaneous vac- available single-dose 10-dose Fifty-dose available single-dose sterile 10-dose sterile clear available capsular isotonic meningococcal intramuscular single similar other polysac- pneumococcal effective younger typical independent age-dependent poor younger poor protective younger measurable first single healthy antibod- detectable vaccine-induced likely school-aged least younger more younger older single similar single meningococcal similar least fourfold serum bacte- asymptomatic respective little older single same other different anatomic relative younger highest sporadic short older routine 2-10 available available same other separate separate unvaccinated high Other meningococcal ſºon-kotnvasive meningococcal acceptable available * :1-21 meningococcal 11-55 meningococcal military acceptable hyperendemic available terminal functional anatomic :1-21 occur meningococcal —military annual geographic hyperendemic —terminal anatomic :1-21 same other separate separate meningococcal vaccine-preventable probable primary meningococcal less primary more population-based age-specific a-3 meningococcal applicable vaccine- other vaccine-preventable meningococcal probable primary —period * Population-based age-specific Such i * older first acceptable acceptable asplenic endemic longer available next present i local such last i 1-2 such systemic adverse similar frequent local such systemic severe severe anaphylactic allergic further severe routine minor vacci- adverse available severe i Single-dose multidose meningococcal most healthcare invasive meningococcal local sporadic meningococcal antimicrobial oral mouth-to-mouth antimicrobial direct sporadic meningococcal greater total meningococcal higher general secondary highest antimicrobial possible less limited nasopharyngeal helpful preventive effective acceptable antimicrobial chemopro- antimicrobial other other third- other chemoprophylactic Active provisional meningococcal meningococcal young meningococcal meningococcal laboratory-acquired meningococcal meningococcal clinical infectious human Chinese derivative first intentional susceptible great last intensified global last indigenous global Other large brick-shaped different other other other other aerosolized greater viable several longer low higher such major severe Chinese late Last Last indigenous viable chemical regional oral major severe severe important multiple different other many natural other such first western central susceptible regional asymptomatic further first prodromal small oral characteristic clinical different distinguishable such major severe higher greater major last major first severe = many last last indigenous principal clinical major relative clinical ordinary mild flat severe uncommon febrile usual asymptomatic common infectious more smallpox unvacci- nated ordinary prodromal third fourth better red oral ulcerate large cutaneous visible highest infectious few proximal distal uncommon uncommon 2-4 infectious mucous red ulcerate highest first skin 2-4 proximal second third third fourth vesicular 0-1 erythematous 6-12 central 13-20 pustular 21-28 flattened common other pustular sixth seventh small second third seventh eighth high single particular tral same different more * same more Most centrifugal general clinical numerous severe ordinary-type •Rarely fatal typical few numerous fatal major Flat flush ordinary-type cer- large flat-type soft severe little severe Most fatal severe toxemic extensive seventh eighth flat ordinary-type little umbilicated soft common flat-type most fatal severe uncommon extensive mucous gastrointestinal large Indian pregnant mucous prodromal dusky little early hemorrhagic second third other mucous seventh few insignificant cutaneous present hemor- early eruptive flat severe sudden normal other significant such true subclinical major serologic subclinical bacterial uncommon eighth overall ordinary viral indistinguishable due fatal sixteenth clear overall ordinary-type greater less smallpox common due important other most important other other severe high least Most short severe other additional such abdominal normal important classic different deep superficial uncommon single same more centrifugal several same new several more severe useful maculopapular other febrile such other Other common least limited vesicular adverse recent 1-4 Other hard • same rare such rickettsial small present hemorrhagic flat-type lethal common varicella-zoster viral elderly dermatomal classic regional possible pattern external mucous 1-2 maculopapular whitish- flat oval peripheral major febrile high low major higher least systemic least additional deep abdominal deep same umbilicated severe abdominal same greatest distal first oral individual high major sure local possible infectious such high other major more minor high infectious possible low fewer minor available //www.bt.cdc.gov/agent/smallpox/ high clinical probable other other clinical distal oral classic same major minor diagnostic specific acid-based clinical high available other nucleic acid-based such direct moderate important rapid diagnostic infectious clinical predictive positive low smallpox clinical false-positive serious common common false rapid diagnostic important rapid available clinical useful direct anti-VZV sensitive specific dependent careful vesicular rapid clinical consistent diagnostic available least private academic large local Other simplex diagnostic available local positive available medical clinical clinical local critical infectious major person-to-person airborne trans- fine airborne negative same other infectious such appropriate disposable other susceptible protective other Reusable such laundry appropriate supportive antiviral antiviral useful therapeutic serious renal off-label other investigational new infec- tious public Most transmission hospital large airborne frequent natural chronic early global known airborne oral Most direct infected physical viable dried uncommon infectious first infectious first trans- frequent most skin intact present longer frequent general infectious slight high severe prodromal medical frequent unrecognized global next effective low similar highest tropical seasonal evident last early global initial least sur- numerous national epidemic civil other difficult cultural apparent low global Last indigenous enormous last last more particular intensive last difficult few difficult intensive last indigenous additional more last fatal global clinical higher deep-seated same other apparent atypical such flat-type low high high smallpox successful severe rural same same distinct available live infectious current early freeze-dried 100-dose small available effective safe full-strength additional immunogenic additional special vaccine needle civilian available genus-specific cross-protective other detectable primary primary unknown primary percutaneous primary higher higher second smallpox high primary substantial more high longer greater primary less severe 1950-1971 > vaccinated unvac- < 11-20 125:161-9 secondary lower unvac- lowest secondary less severe primary primary clear Jennerian pustular third permanent major successful major similar primary primary typical other major equivocal several possible equivocal immune viral allergic compo- equivocal incorrect general equivocal possible available available present other such other important primary viral successful major immune viral incorrect severe modified-type vac 3-4 5-6 7-11 8-12 typical military occupational other other smallpox intentional non-highly f lab military other infect other other other such recombinant clinical recombinant recom- public other smallpox intentional initial direct medical public clinical infectious such responsible medical other medical military public initial suspected infectious Other public successful major routine occupational other nonvariola least increased empiric successful old new unvaccinated average average average larger specific clinical bacterial severe mild moderate normal common recent higher higher common constitutional ninth common higher higher successful * —can lymphadenopathy 3-10 Susceptible recreational present viral inadvertent 25-529 23-242 trans- 10-39 frequent inadvertent primary common Most specific other significant * Most eyelid erythematous urticarial specific rare bullous other other normal Most normal minor little minor little i limited residual serious i primary severe progressive post- vaccinial least primary frequent older primary life-threatening adverse adverse serious cardiac civilian ischemic localized systemic active severe fatal serious active severe progressive metastatic cellular humoral primary fatal common human post-transplant aggressive antiviral primary postvaccinal younger primary central nervous such Most allergic direct viral nervous complica- permanent specific postvaccinial rare fetal primary early active severe fatal metastatic immunologic cellular fatal older primary allergic neurologic early rare allergic Physician-diagnosed primary postvaccinial progressive adverse available //www.bt.cdc.gov/agent/smallpox/ severe allergic prior sulfa-type new significant many solid cellular humoral significant immunosup- high-dose higher higher immunosuppressive live other live high last physician-diagnosed such late adverse physician-diagnosed current first pregnant pregnant least close other chronic exfoliative inad- exfoliative chronic exfoliative young other occupational public younger severe same current severe intravenous i available solvent/detergent-treated sterile human healthy ocular high anti-vaccinia plas- postvaccinial human severe such eczematous such aberrant other special due effective adverse animal unclear vac- investigational new careful second-line smallpox investigative stable vial early intentional interim local key detailed critical local critical other critical certain military civilian certain overseas general other critical certain high certain overseas general public diluted smallpox vaccinia-naïve military biological medical public national statewide national new temporary zoonotic spore-forming Greek black biblical Indian human contagious first microbial first live animal live human cell-free cell-free large aerobic spore-forming gram-positive common such long viable infective many potential direct sufficient such proteins—protective lethal lethal responsible biblical aerobic viable responsible mucous intracellular antiphagocytic effective vegetative cutaneous gastrointestinal clinical —cutaneous common natural rare clear extensive vegetative cationic lymphatic large widespread organ tracheobronchial mediastinal extensive massive alveolar lymphatic effective vegetative effective nonvegetative therapeutic numerous cutaneous gastrointestinal clinical cutaneous gastrointestinal human cutaneous anthracis-contaminated other cutaneous small pruritic necrotic characteristic black Other adjacent cuta- neous initial cutaneous antibiotic antibiotic intestinal regional lower acute abdominal gastrointestinal unknown common intentional median first bioterrorism-related several non- productive 1-12 necrotic black 1-7 oropharyngeal cervical abdominal 1-7 radiographic mediastinal antibiotic antibiotic bioterrorism-related prodromal high pleural due case- intensive similar early other other such runny common common common common Most chest most abnormal primary secondary bacterial cutaneous characteristic black clinical vesicular typical gram-positive pleural ypical difficult other severe gastrointestinal PA-based typical helpful difficult useful clinical bacterial great advanced visible unspun peripheral Gram-positive other clinical such pleural oropharyngeal cerebrospinal positive Other pleural PA-based specific capsular important therapeutic sensitive several additional active oral –30-60 such resistant other such bioterrorism-related antimicrobial active previous apparent antibiotic therapeutic previous intravenous least other active intravenous oral aggressive such pleural acid-base mechanical cutaneous first-line cutaneous systemic extensive simultaneous cutaneous cutaneous eschar current common agricul- tural cutaneous gastrointestinal rare human communicable rare cutaneous main resistant physical many dormant certain common direct cutaneous such important undercooked airborne industrial larger difficult able smaller small lower rare rare other animal animal rare other laboratory-associated animal rare effective contagious cutaneous rare most anthrax-infected anthrax-contaminated true human difficult unreliable largest recent human annual human early Most cutaneous single cutaneous 20th recent domestic animal single other intentional 1951-2004 veterinary live veterinary cell-free human cell-free other cellular small preservative direct compatible cutaneous gastrointestinal other least supportive compatible alternative compatible environmental corroborative local first live live unencapsulated principal veterinary occasional unsuitable early 20th first human minimal short-term human protective protein- free FDA-licensed human cell-free fil- dead live principal responsible detectable first human fourfold cutaneous clinical alum-precipitated PA-based cutaneous available younger older protective alum-precipitated several animal different human protective neous annual annual other entire extra six-dose primary local intramuscular subcutaneous similar high routine clinical certain military animal low other high certain military other select intentional first federal medical private available nonhuman post- protective effective current optimal human vaccine-induced more fourfold clear nonhuman sufficient common adverse local minor local less moderate local severe local more Local several multiple systemic common rare several due local more injection-site effective effective PA-based • current FDA-licensed various doxycycline severe significant adverse few short-term 25-year unusual unexplained life- adverse general long-term adverse possible several scientific available younger older high specific local systemic available severe anaphylactic allergic severe adverse severe severe adverse low-grade m potential potential related adverse necessary suboptimal demon- such effective effective non- human other less similar former lethal initial Such inadvertent biological more * third pregnant 10-15 antibiotic possible antibiotic antibiotic suscepti- antibiotic susceptible minimum attainable oral potential antibiotic available standard 3-dose effective subsequent additional cutaneous gastrointestinal rare gastrointestinal possible current expert clinical antibiotic prolonged least likely ffensive biological offensive biological stable many high least unknown likely biological high greater other potential biological other postal direct several direct contaminat- antibiotic available intentional interim public bioterrorism-related interim antimicrobial cutaneous bioterrorism-related human systematic biological safe A-1 A-2 A-15 Antibody-Live //www.cdc.gov/nip/recs/child-schedule.htm Spanish black white 4-page 2-page accessible Downloadable commercial //www.cdc.gov/nip/recs/adult-schedule.htm black white 4-page 2-page commercial accessible last adolescent routine subsequent feasible special other significant adverse available 800-822-7967 old possible possible HBs.Ag-negative rare original HBs.Ag-negative laborato- medical vac- second final permissible positive next well-child acellular fourth early third unlikely acellular 11–12-year single primary final least first second susceptible reliable ceptible least Meningococcal old unvaccinated high Other formeningococcal fresh- meningococcal acceptable invasive meningococcal terminal anatomic functional certain other high RR-7 acceptable pneumococcal certain final certain high-risk certain limited cardiac human other high healthy healthy influenza-related healthy acceptable intramuscular vac- least least least new routine 1-year-old certain high American • More minimum final first current necessary final final 12-14 current second previous final current necessary current final turnal final current current healthy healthy previous first current necessary fourth fourth current first third final all-IPV all-oral fourth least second necessary third current primary last further 3-dose second 2-dose susceptible adverse federal additional 24-hour national toll-free 800-CDC-INFO 800-232-4636 vaccine-preventable local recommended medical other complete significant available 800-822-1961 available 800-338-2382 1-dose broken populators- other medical other prior 202-351-6400 available CDC-INFO 232-4636 § 1-dose || 4-8 | 1-2 6-12 * co-e chronic end-stage renal pulmonary elective chronic cerebrospinal long-term other present medical occupational other prior American high severe high young institutional correctional military nonpregnant age-appropriate least parental typical non–U.S.-born atypical epidemiologic typical labora- pregnant pregnant chronic chronic renal cognitive other neuromuscular severe secondary severe long-term Other other long-term high in-home high-risk uncertain complete primary toxoid-containing primary least third dose second last wound American single full pediatric tetanus- diphtheria-acellular available immune medical second unknown postsecondary educational other measles-containing severe laboratory unreliable child- pregnant pregnant healthy nonpregnant special chronic pulmonary chronic renal nephrotic functional anatomic sickle elective least immunosuppressive congenital immunode- close possible highest multiple generalized high-dose long-term Other certain American Indian other long-term pneumococcal chronic nephrotic functional oranatomic sickle immunosuppres- sive marrow high-dose long-term one-time primary chronic illegal Other high intermediate 2-dose special other allied previous Other chronic correctional international high chronic anatomic functional Other first-year military meningococcal hyperendemic epidemic sub-Saharan dry local annual acceptable high epidemic available older chronic good American dose next next dose 1-4 1-4 2-17 6-18 DTaP-2 DTaP-3 6-12 15-18 influenzae Hib-2 Hib-4 12-15 IPV-2 2-14 |PV-3 6-18 IPV-4 Pneumococcal PCV-2 PCV-3 PCV-4 12-15 MMR-1 ” 12-15 4-6 º 12-18 ºf 12-23 6-18 18-41 6-10 acellular available separate equivalent American minimum oldest individual minimum equal greatest individual available less old other least least least first older fewer older pneumococcal young old younger older first congenital RR-8 older least younger old first younger first younger influenza older second meningococcal high meningococcal second acceptable RR-07 previous previous tetanus-containing * second highest serious pneumococcal likely rapid pneumococcal previous highest severe pneumococcal younger pneumococcal ：-） ſ- ºooo-lºº uouuzunului uosui， uouov uofficznunului opow-wºw uelqo uſ jou- uonnebøua oubyen uomocou uoueoſ uoue uowae 11- pinous uleuo：| suºsiođe suÁ9-t 1-9 uur ubupių， ºuroopa ºutunenuos-proxo uønje uiuuw uolueoſ uogop uoſ uiuiae uo uiuuw uonnebau） uonesipurunuo， uomocou uo uomocou uç uoleſ ulo ne uut uouiſì uoue uu9 uomið trae- uonje uovº ulouſ uoſ ºinpouss （sop-， a-xuosuuſ unde tºº-ºº un uo-t uou oinpoubs a-xuoºuza ºs op-， uo ur '-0 uoo ne uooaenoq uoo uonnºsau） sºuºsºsop-g- uomocou uopeoſ upisau uoupliųo unuluw snowoud （pd-soordine u u uno suÁzſ-11 uopliųo uorsooq uy uomocou uoºuno， unupiųo uovið |- arid uoupliųo ruusu-şi sous uzi • suÁ9-t （uusi-si uuq uz uiuuw upju uourou ſe ºud-i uuoqwou u uourou uu9 uſųųw uuoqwou øanısod-ºvskih ubųnou u uu9 uç 1-zı usºnup-oſuus unui uoluro uowae plnous uſ uus 1-9 osop uuz-ı loud ušnouum uoupių， uoupotpununuo， |- uøųno uoneuropew dn-ųomeo uou unumour uomº uæquo uoneuropea uonov uoneziunului uouuz unului uo uoſ uo uun |-|- uſųųw uomocou pinous uoºunoſ uoupių， quidoosns- uzi usuplių， uſųniw ubauð uspio uuzl uoupių： uusi-zi i awuſo- īnī£5，55755ītī5põWT|- uonnexou uo uwoux uxo |- olloqehou ºupno- uopun un uopuosip oud-|ºsłºwę wuuu-usuu Į ，|- ）|- uso use-9 unupių， |- ne ‘ suÁó-vuº sosop owo-¿ uugz-oplių， out- uo su-ſe uo uonnaeyðu… ojco-siuojųo un uonounjsÁp upou （su oweų- uſz-9 out- uopeoſ unuo，oouw uoupių： ut uoezuanuui sºwº-rioj uºstº un suh- uo uºaſă |-|×- | ssop-ųāų uo ui uaajºuſinqola oarų pºz istol- ubauð uuou-ſºuoſ uspoſ ir uoqaeunaeJ|- untriloqnu uo uºaſă usoop uzi uo un uo uomocou onbelºu suÁ9-t owo-| uomið pinous esop v-ººr uusi-zı |-|- uouocunuui uo uppuauuuuooºx u uºaſă uo uoqae uo uomiº ſpuolunųswº-tº plnous uºploſou noſ ºps-，| uonroſpunenuos uæquo uou uoquour uouº upo uøųno uopeupbea uoņezĮunuuuul uoſ other related mild 12-13m Previous anaphylactic unvaccinated compo- last previous |-Hib interchangeable different previous severe necessary primary “ 7-lim |- older least dose dose • |-Dose early younger anaphylactic least unvaccinated high-risk give older previous severe acute next High-risk anatomic/functional previous pulmonary least iſ least previous least final high-risk anaphylactic older older dis- functional anatomic least previous severe least previous anaphylactic older -Live local older severe -Wish high |-l other ococcal older younger older functional terminal meningococcal hyperendemic epidemic dry Other meningococcal anaphylactic neurologic severe acute younger ：-） |- 5-O- 5-O- uuam） uotsiatou untuð uoſ uuentiae uorsuo， usia u uou- uonne！ uomocou uolueoſpuſe uoaſă uon uoneuropea ou ouin-ºuo- uwouxun uoneuroopa æsop wun-suo uoaſă uod ununul ut ſcual uripul urouxiiv.05 uso uneluxo ui uusiſoqoole uossoulli noe uonipuo： uºpuosip uouro uonbcou uonnesºud uomocou uolueoſ uut usquios（x） ut umboo uoneuroopa uºquomo uomio uouov uouuziuntuur own uolneziunului uo uºpuoluuuooº u uuou ut uo o uopluſo ubenuo， uxuo low ourouſe：H-czubnuuſ un uwae uou uolneuſų|× usò suÁór daud-uou uuſ ut uo oä uopſtilo ºurou-jo-ino uostºs ou uwiſow su-ne uniw suosuºd-pwt uolueildse ueb suosisa-l u leaſul|- suosiºn-ezuanuui| < ：-） ſ- 5-O- uon ºmej：pow- uomocºu uſºwen ueb pº utni |-ºutosex uon |- uolºq noe |（siux-moduloo uomocou unuo.O loi suonºpustintional un ut own uogi unaised uz 1-9 un usisooq 10- un uoueumquo nou own uio usawae uou |-|- uou susuoduos snowoud uoueo io-1 ucis ubow.lºq usº usownaq uit isu-ų3ıH uo unoſ umsooq uºlºq upuxº un urchqo |- uoneuropea sonuotant |-cu ut uoloeſ-ºſuuſolo uniw uoui uotu uw utdei ubojos ul upijo suosiad aansod-ºvskih umcuxo sonuſuoti uuon-ſuoi |-p umcuxo ut uniw ut nºuurd utin usºnour ulupe uoſ uoueussew uuouw uod |- uoană nou upis ulInpuºqni uoneopunenuo， uoſitae ut uavnº unqolae 11- uonesipunwujuos uonepcu osop-iſºmų uuni uomocou unulow ucun uouoos ut uouſow uomið pinous uoneuropew upuſow low uuoq own pinous uºſtų uolųno uomocou uoueo ne uoneopunenuo， uoli uopuauuuuooºx oos u u^ 11- ºsop-iſºmų uo ºnow uondºpenuoo uuni uomoeau o uo ubus uo uostº uontuottinoop plnous uſoq u uloq ſurnuliw-.bs× susidoſomųojonyw -ºpuſ， （ſºunt-ox1 uostos- ump ucieuſes-qns uſoq upiųw u u suosiða- luotuºſduloo ſtuttual uneluopun uoli upo uodoj uſ uolue ut ut pinous sumpt uoquour ubanº uco immune different monoclonal negligible Whole 80-100 intravenous maximum syncytial immune 300-400 immune entire additional immune syncytial asymptomatic symptomatic other immunosuppressive 3-dose dose anti-HBs serologic prior primary 3-dose on-the-job fecal 3-dose 0- 1- 6-month least ml positive ml negative unpro- 3-dose positive —If negative consid- susceptible probable parenteral possible per- positive positive Anti-HBs original expo- anti-HBs negative non-preg- nant healthy younger annual out- immunosuppressed protective medical desirable equivocal appropriate first more least live least live acceptable rec- unvaccinated reliable effective commercial sensitive vaccine-induced 3-dose primary tetanus/diphtheria-containing necessary acellular unavailable accept- able recom- additional specific official state- www.cdc.gov/ nip/publications/ACIP-list.htm • A-19 humoral X-linked common variable live uncertain humoral severe selective Other live safe effective cell- humoral severe complete live ineffective most Wiskott-Aldrich ataxia- effective late effective granulomatous secondary bacterial safe effective safe effective routine bacterial viral yellow granulomatous inactivated effective bacterial effective renal effective bacterial viral yellow routine 71-72 1-18 primary 4-dose 3-dose Act-IB 4-dose pediatric vial 6-35 prefilled Intra- viral Japanese viral viral viral viral viral viral bacterial eningococcal bacterial 11- bacterial bacterial viral viral viral viral bacterial bacterial toxoid bacterial bacterial viral viral taneous inactive necessary pharmaceutical vac- other immunologic suitable further pharma- ceutical reasonable manu- human oral green residue Ethylenediamine-tetraacetic preservative solvent nese oral most most oral residue Japanese cellular residue antibacterial red phenolsulfonphtha- most most glycol p-isooctyl- viral inacti- nonyl viral inacti- most solvent Yellow multi-dose precise contain- tidose Japanese single-dose stable unspecified combi- fertilized Yellow YF-Vax Stainer-Scholte con- extract green Japanese meningococcal fetal DTaP-Hep Synthetic/semi-synthetic * Canadian thi- joint 48:563-565 1387-92,1397-1401 harmful preserva- 112:1394-1401 unspecified 2-Phenoxyethanol 2- 2-Phenoxyethanol 2-Phenoxyethanol 2-Phenoxyethanol cº-Tocopheryl multidose p- multidose 2-Phenoxyethanol 10-dose unspecified Ethylenediamine-Tetraacetic 2- unspecified 2- oral refrigerator- stable Ethylenediamine-Tetraacetic equivalent thimerosal-free biological additional decreased equivalent thimerosal-free post- biological single adult/pediatric preservative free preservative free multi-dose preservative free 2005-6 MENOMUNE-A/C/Y/W-135 multi-dose single _M-M-R Wyeth-Ayerst dose dose dose dose f dose sax.56 −r-— dose pack-1 dose dose dose 11-15 º |Hip- dose seasz2.53 sanofi dose dose sanofi B-14 dose sanofi dose dose preservative dose dose dose dose dose dose preservative dose dose dose preservative =-m many international many foreign many Vaccine-Related difficult international Table Several Western European available comprehensive complete many international complete acellular acellular whole whole whole Chemo-Sero-Therapeutic whole live military human immune human 1987-1989 whole live yeast Chemo-Sero-Therapeutic live military pediatric acellular acellular acellular generic acellular generic recombinant whole Tick-borne whole whole whole recombinant plasma-derived live 1969-1979 live 1970-1973 immune acellular whole whole inactivated whole Japanese live live live live whole whole live generic live live live live live live live live live generic generic whole oral whole oral oral pneumococcal 7- acellular acellular pneumococcal 23-valent 7-valent 7-valent live 1959-1968 syncytial generic live live live generic live live live generic oral live live oral injectable live immune immune generic oral acellular acellular acellular live acellular acellular live oral live live pediatric live oral parenteral injectable parenteral live live live injectable live oral live live generic live live North American many complete Serbian Spanish German Japanese Romanian Spanish Serbo-Croatian German German Serbian mºd German French rengkong Spanish Japanese German Norwegian Spanish Spanish convulsive Spanish Romanian Serbo-Croatian Serbian Vaccine-Related > |- Indo-European Western European Italian Norwegian Spanish tº- |- – |- |- i C-1 C-12 C-13 C-14 vial multidose earliest vial vaccine-Pediatric —Pediatric vaccine-Pediatric Single-Dose frozen Manufacturer-Filled Special earliest vial manufacturer-filled vigorous frozen current vial earliest frozen dry white red further own exterior frozen manual frost-free necessary Careful necessary frost-free new 2005-2006 2004- current impenetrable Special earliest live ſ |-T frozen vial frozen vial ulgate 7-Valent homogenous white vigorous Special vigorous haride multidose severe local dry dry present frozen separate last standard Dormitory-style appropriate necessary Careful necessary other 1-800-609-4618 earliest live | sanofi 800-822-2463 baverhe 800-288-8371 drug-service 404-639-3670 800-200-4278 medical 617-983-6400 general 800-635-1766 vacGre settle hold-style corrrrle-cla-style d-ºrruto separate o- uſes cric so-natthe longest shortest hose wil refrae-a-or extra cold other Ice-filled old next urjamaged va-cne manufac- aſſe-led detailed local cº-5 least monthly earliest large stable open electrical electrical perishable immedi- auxiliary other local ngdº-49 Expensive electrical electrical electrical m-m critical clinical practical general supervisory professional American state/agency-related competency-based active Many other available inaccurate misleading other reliable open safe informed multiple important health-care uncomfortable ºr subjective multiple individual previous important vapocoolant non-aspirin-containing age-appropriate Age-appropriate non-pharmacologic separate next • single effective good alcohol-based antiseptic mandatory vaccine potential open important needle stick appropriate follow-up state/local accidental needle medical critical separate parenteral engineered available many needle stick potential clinical optimal needle viscous fine 22-25 Needle-free new needle-free needle stick health-care needle-free last lyophilized entire needle necessary possible equal vial needle mº- vial positive allow single entire vial excess difficult Other possible other immediate large few few clinic immediate live unstable identifiable recommended imperative severe local adverse adult- adequate 22-25g adequate deltoid 22-25s 1-2 mL- live intran-ai upright adequate 22–25-1-2 young 23-25-5/8- s-ºrg young upper 23-25s deltoid young 23-25s 5/8- upper adequate 22-25-1-2 young upper 23-25s young 23-25s 2-dose tº adequate 22-25s 1-2- 1-2- complete particular usual thigh upper necessary upper | 5/8-inch 23- 25-gauge needle appropriate circular light several dry several lateralis anterolateral upper femoral \_-Sciatic intramuscular middle femoral older adequate -Deltoid 22- 25-gauge needle needle adequate typical various 7/8- 1-inch older 7/8- 1/4-inch 1- appropriate circular acceptable pediatric geriatric needle light several dry new entire multiple same more same 1-2 local maximum same deltoid same necessary acceptable different specific familiar other similar 23- least • vial natural severe anaphylactic rare local individual necessary primary health-care • vasovagal vasovagal allergic supportive life-threatening allergic initial current detailed medical allergic rare 15-20 permanent medical common lower lower right state/local complete available clinical safe effective appropriate private pediatric self-assessment annual perfor- corrective appropriate safe effective annual pediatric medical probationary several special comfortable thern applicable medical clinical up-to-date vial new iden- probationary aseptic needle disposable appropriate subcutaneous anatomic specific appropriate steady gentle several dry needle live applicable due other proper other refresher attend cultural 30-day 3-month Berkeleyway-Berkeley.ca94704 follow-up 1-12 22-25mm 22-32mm 25-32mm unuuuu uo steady other other lish nº | servº- federal current recent 3-month-old vaccine-associated paralytic first sequential live current serious many Most adverse self-limited such rare re- ef- safe possible important parents/legal ob- jective dis- ad- common mild vac- standardized objective infor- adverse un- informa- intense prop- minor legal address con- parent/legal repre- mandatory pneumo- coccal vac- available pneumococ- cal yellow typhoid vac- re- federal meningo- coccal local individual other legal NCVIA-covered tered parent/legal representa- current available objective jour- ap- imperative current Most current recent available local available several complete current effective pneumococcal current legal such such relevant legal long-term single other quali- minor visual oral permanent medical permanent medical legal additional applicable camera-ready available available §300aa-26 available other E-2 current available single hard new available Spanish compatible available more French Armenian German Laotian Serbo-Croatian appropriate informed tear-off technical infor- enough procedural oral substantive medical informed appropriate legal same legal legal other legal legal representative sure representative adverse new final new adverse previous new visual oral unable least compatible available old obsolete adverse multiple identical different recently-dated valid current adverse clinical likely |-T traditional difficult standard reliable multi-syllable understood individual long easy useful several low racial ethnic available meningococcal available own own other other prior E-6 legal present school- adolescent legal medical permissible single entire such acceptable first legal complete possible approximate future additional initial legal original additional earlier next original additional medical additional additional significant adverse earlier adverse previous medical main at-lance-vaccine El-tin-i-tº- sheet-produced center-for-o-º-º-control legal representative-both benefit-and-risk- and-tº- int-tº-letton- -given new -it- 1-poºl an- nºn- other nºt recent Last in-ni- in-tº-hudian |- main printable other languages- º text-only- printable screen-reader accessible able audio Reportable F-2 national most describe such serious such important new Most other adverse significant adverse such unsure next adverse pre-addressed 1-800-822-7967 printable more e-mail toll-free toll-free Reportable |- anaphylactic additional applicable insert anaphylactic additional applicable insert additional anaphylactic applicable applicable additional 7-30 viral applicable additional insert type a- viral applicable additional additional anaphylactic applicable insert anaphylactic applicable additional additional additional applicable additional |Pneumococcal additional reportable 300aa-25 significant unexpected certain adverse anaphylactic severe lethal systemic Most few laryngeal other peripheral single peripheral central spinal nervous deep severe upper upper notable clinical such applicable such severe associated least follow postictal older least least significant mental confusional independent intracranial clinical clinical least greater absent painful other absent external familiar clinical sig- nificant mental high-pitched unusual inconsolable other first neurologic applicable least vaccina- normal neurologic encephalopathy residual neurologic subsequent encephalopathy preponder- chronic secondary genetic chronic encephalopathy metabolic structural genetic bolic structural genetic chronic continuous more Medical chronic such connective limited systemic systemic mixed connective fibromyal- infectious other direct immune metabolic dis- neuropathic joint chronic invasive sterile clinical invasive radiographic positive invasive bacterial Reportable ºf www.vaers.org 1-877-721-0.366 Toll-Free Last Responsible different || adverse appropriate diagnostic other Other clinic unknown Pre-existing physician-diagnosed medical adverse applicable 300aa-25 other voluntary more separate essential possible such Reportable other serious other adverse adverse legal adverse 09-20-0136 legal available available legal same adverse Such local general same possible more adverse serious negative normal relevant other short pre-existing physician-diagnosed medical adverse previous more prior additional old no-fault traditional compensible individual vaccine-related medical special eligible special Compensable non-compensable civil peti- anaphylactic 2-28 applicable antigen-containing anaphylactic applicable anaphylactic 0-4 5-15 applicable virus-containing 7-42 applicable virus-containing 7-30 0-6 applicable live non-immunodeficient 0-30 immunodeficient 0-6 applicable viral non-immunodeficient 0-30 immunodeficient 0-6 applicable applicable anaphylactic 0-4 applicable antigen-containing anaphylactic applicable applicable applicable applicable live oral rhesus-based 0-30 applicable applicable new applicable routine more www.hrsa.gov/osp anaphylactic severe lethal systemic allergic few cardiovascular Other significant clinical lower minimal spleen significant such applicable such more associated least postictal older least significant mental confusional independent intracranial clinical clinical least greater applicable painful other absent external familiar clinical significant mental high-pitched unusual inconsolable other first neurologic applicable least normal neurologic encephalopathy residual neurologic subsequent chronic secondary genetic prenatal perinatal fac- chronic encephalopathy infec- metabolic structural genetic metabolic structural genetic vaccine-related possible preponder- encephalopathy shall- entire medical myoclonic tonic-clonic grand complex partial chronic objective continuous more chronic such connective rheuma- systemic systemic mixed con- nective vascu- infectious other direct immune metabolic neuropathic inflammatory joint chronic upper other peripheral single peripheral spinal nervous deep steady severe shoul- upper weak- upper notable clinical present same opposite bilateral upper physical electromyographic consistent attributable brachial distinguishable con- peripheral other peripheral central nervous cranial less Thrombocytopenic other such previous lymphoproliferative hemolytic uremic intravascular bacterial viral human antecedent clinical normal normal Vaccine-strain viral specific monoclonal Vaccine-strain viral vaccine-strain sufficient specific º * Vaccine-Preventable 1950-2003 20th 1962-2004 1950-2003 paralytic reportable other other invasive notifiable 1971-2002 Reportable 1950-1970 respective paralytic est 1900-1998 1962-2004 measles-containing more measles-containing more measles-containing represent 2- year-old represent 19-35 month-old national recent 19-35 H-1 H-21 H-40 1133-7. available H-3 H-5 H-14 public private local public private essential desirable medical public important national vac- cine-preventable several important private primary critical such national preventive high important experience- ready vaccine-related inaccurate many American federal local professional 2001-02 medical public inclusive many clinical mid-level physician medical clerical useful public profes- desirable current difficult little best clear necessary own adoles- feasible likely available other possible Effective appropriate easy-to-understand appropriate accessible knowledgeable receive on-going many pos- complete accessible adverse aware separate due overdue Office- clinic-based per- community-based available main such physical necessary other possible comprehensive primary routine other other subsequent primary primary iden- well-care age-appropriate educational physical important sufficient available easier =- Out-of-pocket costs-including fees-should low possible low possible Free available public reasonable local aware setting-private covered high preventive due medical prior adverse available available www.cdc.gov/nip/recs/child-schedule.htm other relevant medical Effective appropriate sufficient hand-held adolescent federal vaccine-specific necessary oral other appropriate adolescent adverse medical necessary =-m 1-800-232-0233 Spanish latest available numerous other www.immunize.org national appropriate appropriate available local available 404-639-8222 accessible safe effective vac- adverse consistent up-to-date knowledgeable receive knowledgeable receive adverse other other specific responsibili- distance-based satellite web-based self-administered available many possible same American safe effective certain simulta- neous earliest simultaneous accurate complete accessible accessible medical rapid federal medical primary primary local available complete useful new hand-held pro- available adverse aware separate significant adverse certain adverse medical possible aware no-fault aware separate | 1-800-822-7967 available 1-800-338-2382 other available due overdue due overdue specific high medical previous intensive due overdue other automatic clinic-based effective low local community-based highest possible vaccine-preventable entire opti- vaccine-preventable high underserved Community-based public other such Special Supplemental serv- 19-35 20:28-31 21:243-249 free physician public medical 184-186 available American Physician American School-Based infectious adverse public private local governmental ex-officio valuable available American successful vaccine-preventable similar older younger high older younger high pneumococcal susceptible routine vast vaccine-preventable average influenza other invasive invasive pneumococcal due young unpro- congenital safe effective available high certain racial/ethnic pneumococcal comprehensive nationwide vaccine-preventable dramatic current pneumococcal older annual pneumococcal national less high due medical behavioral environmental greater professional private specific nontraditional recent comprehensive previous evidence-based possible available personal desirable major professional public private neces- sary useful current additional available available valid available simultaneous accessible due overdue Regular Patient-oriented community-based available vaccine-preventable recommended meningococcal international physical additional educational mate- appropriate patient/guardian con- sufficient patient low possible older patient private vacci- basic new initial annual medical certain preventive pneumococcal valid invalid prior adverse current valid invalid valid native possible public private available other profes- ample available medical sched- adverse consistent CDC-recommended available significant adverse follow- medical aware encour- available 1-800-822-7967 no-fault compen- aware available 1-800-338-2382 separate Such brief adverse other public other medical more individu- simultaneous indicated safe effective Simultaneous adminis- combined pneumococcal same separate safe effective accessible accessible loca- medical unnecessary medical such influenza paper-based personal medical available available other first annual appropriate vaccina- available due overdue due overdue specific high med- intensive due overdue other specific general available available other insti- tutional enable non-physician such direct physician administrative such physician available Regular such per- other local available available Patient-oriented community-based exam- other such other profes- local 1-28 syncytial 289:179-186 invasive pneumococcal antibiotic 1995-1997 invasive 1995-1998 285:1729-35 1993-1997 greater equal Vaccine-Preventable 725-729 1133-7 1-13 Vaccine-preventable vacci- Physician American School-Based infectious adverse public private vac- local repre- governmental ex-offi- valuable public many professional social vital easy public much harder public important public public public governmental public other public voluntary community-based other public essential public essential several national federal public public essential public overall public common public physical mental ten public public valuable promising essential general public specific programmatic com- good other critical public public major public essential essential public public broad personal healthy individual personal unavailable public personal per- sonal population-based new innovative 2'- preventable major safe available Several low inadequate aware- medical public private federal major public major clinical financial public private vaccine-preventable dis- vaccine-preventable new prac- international many inſec- tious disap- andfatal whoop- indig- enous few congenital ru- sel- re- extraordinary attributable widespread congenital syn- able constant corolete corrºr-tree un 1994-Vol vaccine-preventable strik- fewer vaccine-prevent- able compari- influ- pneumococcal hepa- many child- vaccine-preventable young major such Vaccine-preventable main important costly American several ad- much heavier dis- Table Several ex- limited per- general vaccine-preventable signifi- cant effi- several immuniza- selective universal different different individual larger child- child- statutory communi- few private ne- private in- expensive free most full public avail- responsible high best diffi- same new pneumococcal vac- many new ini- American ſectious next influenza cost- immunization—The 1.-Reported Vaccine-Preventable paralytic 1964-1965 available provisional vacane-associated reportable reportable Table infºuenz- lower current different older potential additional annual different appucable adultim- de- Vaccine-preventable significant strong cost-effective un- prevented less first general high-risk immu- pneumococcal new under- able clinical good organiza- vac- specific de- successful regular public se- vaccine-preventable essen- elderly severe pneumococcal young sexual ac- Many un- clinical public immuniza- admin- helpful older educa- tional other wide- rec- riodic immu- better understand- administrative organiza- tional successful profes- prac- tical vaccine-preventable dis- ben- easy vac- recom- educational espe- announce- popu- efficacious effective local public federal con- epidemiol- vaccine-preventable pro- Table infuerº- 18-24 25-64 second postsecondary educational international vaccine-prevent- able Such vaccina- several mis- vac- vaccine-preventable due vac- high Most ad- wide principal general spe- profession- administrative such such single respon- dif- devel- workable Such common other federal vaccine local com- provid- administra- tive organizational regular stan- regular evalu- financial federal local pneu- mococcal local unpublished pneumococcal vacci- elderly reim- end- renal influenza reim- pneumococ- cal pneu- mococcal pro- adequate important annual influenza little ex- private adultim- organi- such bet- tra- ditional regulatory im- sufficient subject gov- Similar reimburse administra- moni- iden- tified technical financial other private providersfor indi- vidual cov- public oftective adequate vaccine-preventable cºnical insured national pro- immu- vaccine- preventable continu- them- capac- vac- effective efficient vac- clear un- epi- important per- local vaccine-preventable ex- timely ad- current ” under- hepati- pneumococcal inexpensive rapid essential economic vac- cine-preventable immuniza- constant pro- economic vac- es- vaccine-as- costly pneumococcal elderly pneumococcal little geographic great vac- other high-risk more surveil- vaccine-preventable local better recom- current future peri- potential technical regulatory financial legal political appropriate federal detailed specific high-risk condi- inspecific deliverywhere un- fol- pneumococcal influenzaimmunizationamong institution- older least pneumococcal influenza non- high-risk least high-risk antigen-positive least work- intravenous-drugus- essential new vac- important vaccina- older immune responsive initial ef- clinical serious costly economic vaccine-preventable dis- adultim- cur- pneumococcal effective other pre- inter- common elderly epi- vac- greatest several new cold-adapted live pneumococcal acellular new newer adju- epitope-based re- rec- de- vaccine-pre- ventable dis- international dis- easessuch supple- infectious such formerSoviet antimicrobial-resistant many coun- eradi- new be- new vac- new continued microbiologi- immunization—The cal vaccine-preventable immunocompromised de- better economic cur- future vaccine-preventable dis- immuniza- evi- current fu- recom- greater stud- new stable com- greater federal nongovernmen- tal professional associa- interna- tional 1992:3:27:1794-1800 Gen- eral recommen- teta- other Eradi- 10222-229 1989- 1992:43:451-463 congenital 1982267.2616-2620 univer- 1989,84779-784 el in- 1987-1993 Reportable vaccine-preventable 43:57-60 1993.328:1252-1258 medical set- em- 77-725-726 complex sub- stantial immuni- less op- timal infectious im- optimal adverse responsible non- produc- Na- im- elderly 1532106-2111 public preventable American demon- 1988-1992 public pneumococcal elderly influ- enza computer-generated influenza vac- alternative 1990.263:1218-122 Pneumococcal poly- 140-528–530 Comprehensive 1986-1992 toxigenic 501-503 drug-resistant pneumococcal I-1 I-2 I-3 I-4 I-5 I-6 I-7 800-232-4636 800-CDC-INFO Spanish vaccine-preventable single vaccine-preventable related e-mail //www.cdc.gov/nip such online latest downloadable other //www.cdc.gov/nipſed/curriculum/curric-brochure.htm online online viral reliable helpful informative current periodic several immunization-related • toll-free global international É Q- ready-to educational Other other professional federal viral many other useful free 11-19 old much practical e-mail new new hot • vaccine-preventable ſº- _- 35-minute latest Available Spanish different Other payable | 594-21 594-5933 other global national other immunization- Global //www-nt.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm routine Little PSD-IMM-A4 206-2044 562-7802 364-3276 661-2300 883-6015 691-6118 509-7945 ºf 739-2358 657-1463 586-8302 334-4914 524-0967 746-6388 233-7805 50319-0075 66612-1274 831-6292 296-6368 564-4760 483-1909 287-8127 333-5893 Talebian 335-9855 676-5689 Vaccine-Preventable 08625-0369 576-7686 526-6892 444-2920 471-6426 684-8338 271-3850 588-7431 827-2898 12237-0627 27609-3811 58505-0200 10th 474-7381 676-2252 870-4824 328-1412 728-4279 271-6133 @ 731-3095 I-II 685-6806 222-1442 898-0318 773-5509 741-3857 458-7288 794-9937 207-8882 538-9440 lable utah.gov 25301-3715 865-7701 786-0396 235-3590 576-6418 558-1941 @ 267-9493 777-6001 Wells-Fahling 011-684-633-7223 011-684-633-5379 011-671-735-71.43 011-671-734-1475 248-4393 011-692-625-8457 011-692-625-3432 011-691-320-2619 011-691-320-5263 011-670-236-8733 011-670-234-8930 011-680-488-4804 011-680-488-3115 274-5619 777-8762 